ClinVar Variation Id,chr,start,stop,Gene ID,HGNC Gene Symbol,Mondo Id,Disease,Mode of Inheritance,Assertion,Summary of interpretation,PubMed Articles,Evidence Repo Link,Retracted,Allele,HGVS Expressions,Allele Registry Id
586,12,102917130.0,102917130.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF=0.00002; PP4_Moderate: Seen in PKU patients. BH4 disorders ruled out. (PMID:2574002); PS3: <3% (PMID:9450897). PM3: Detected in trans with known pathogenic variants. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PS3). Updated to reflect new PVS1 recommendations.","2574002, 2574002, 9450897",https://erepo.genome.network/evrepo/ui/classification/CA114360/MONDO:0009861/006,False,[T/A/C],"NM_000277.2:c.1A>G, NC_000012.12:g.102917130T>C, CM000674.2:g.102917130T>C, NC_000012.11:g.103310908T>C, CM000674.1:g.103310908T>C, NC_000012.10:g.101835038T>C, NG_008690.1:g.5473A>G, NG_008690.2:g.46281A>G, NM_000277.1:c.1A>G, XM_011538422.1:c.1A>G, NM_001354304.1:c.1A>G, XM_017019370.2:c.1A>G, NM_000277.3:c.1A>G, ENST00000307000.7:c.-147A>G, ENST00000546844.1:c.1A>G, ENST00000547319.1:n.312A>G, ENST00000549111.5:n.97A>G, ENST00000551337.5:c.1A>G, ENST00000551988.5:n.90A>G, ENST00000553106.5:c.1A>G, ENST00000635500.1:n.29-4232A>G, NM_000277.2(PAH):c.1A>G (p.Met1Val)",CA114360
102844,12,102852851.0,102852851.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. gnomAD MAF=0.00007.; PP4: Detected in a PKU patient. BH4 deficiency not assessed. (PMID:9012412). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).",9012412,https://erepo.genome.network/evrepo/ui/classification/CA229778/MONDO:0009861/006,False,[A/-],"NM_000277.2:c.806delT, NC_000012.12:g.102852851del, CM000674.2:g.102852851del, NC_000012.11:g.103246629del, CM000674.1:g.103246629del, NC_000012.10:g.101770759del, NG_008690.1:g.69752del, NG_008690.2:g.110560del, NM_000277.1:c.806del, XM_011538422.1:c.806del, NM_000277.2:c.806del, NM_001354304.1:c.806del, NM_000277.3:c.806del, ENST00000307000.7:c.791del, ENST00000549247.6:n.565del, ENST00000553106.5:c.806del, NM_000277.2(PAH):c.806delT (p.Ile269Thrfs)",CA229778
102736,12,102855281.0,102855281.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: Extremely low frequency in gnomAD. MAF=0.00002.; PP4_Moderate: Detected in 3 chromosomes of patients with PAH deficiency. BH4 deficiency ruled out. (PMID:8268925). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate).",8268925,https://erepo.genome.network/evrepo/ui/classification/CA229624/MONDO:0009861/006,False,[C/G/T],"NM_000277.2:c.561G>A, NC_000012.12:g.102855281C>T, CM000674.2:g.102855281C>T, NC_000012.11:g.103249059C>T, CM000674.1:g.103249059C>T, NC_000012.10:g.101773189C>T, NG_008690.1:g.67322G>A, NG_008690.2:g.108130G>A, NM_000277.1:c.561G>A, XM_011538422.1:c.561G>A, NM_001354304.1:c.561G>A, XM_017019370.2:c.561G>A, NM_000277.3:c.561G>A, ENST00000307000.7:c.546G>A, ENST00000549111.5:n.657G>A, ENST00000551988.5:n.582G>A, ENST00000553106.5:c.561G>A, NM_000277.2(PAH):c.561G>A (p.Trp187Ter)",CA229624
102705,12,102866602.0,102866602.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency. ExAC MAF: 0.00001.; PP4: Detected in PKU patient in international phase II clinical trial for sapropterin. (PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).",23430918,https://erepo.genome.network/evrepo/ui/classification/CA229588/MONDO:0009861/006,False,[T/-],"NM_000277.2:c.503delA, NC_000012.12:g.102866602del, CM000674.2:g.102866602del, NC_000012.11:g.103260380del, CM000674.1:g.103260380del, NC_000012.10:g.101784510del, NG_008690.1:g.56001del, NG_008690.2:g.96809del, NM_000277.1:c.503del, XM_011538422.1:c.503del, NM_000277.2:c.503del, NM_001354304.1:c.503del, XM_017019370.2:c.503del, NM_000277.3:c.503del, ENST00000307000.7:c.488del, ENST00000549111.5:n.599del, ENST00000551988.5:n.530+10860del, ENST00000553106.5:c.503del, NM_000277.2(PAH):c.503delA (p.Tyr168Serfs)",CA229588
102518,12,102843756.0,102843756.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4: Detected in a patient with Classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).",8659548,https://erepo.genome.network/evrepo/ui/classification/CA229336/MONDO:0009861/006,False,[C/-],"NM_000277.2:c.1089delG, NC_000012.12:g.102843756del, CM000674.2:g.102843756del, NC_000012.11:g.103237534del, CM000674.1:g.103237534del, NC_000012.10:g.101761664del, NG_008690.1:g.78847del, NG_008690.2:g.119655del, NM_000277.1:c.1089del, XM_011538422.1:c.1032del, NM_000277.2:c.1089del, NM_001354304.1:c.1089del, NM_000277.3:c.1089del, ENST00000307000.7:c.1074del, ENST00000549247.6:n.848del, ENST00000551114.2:n.751del, ENST00000553106.5:c.1089del, ENST00000635477.1:n.193del, ENST00000635528.1:n.604del, NM_000277.2(PAH):c.1089delG (p.Lys363Asnfs)",CA229336
102498,12,102844346.0,102844346.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Frameshift variant; PM2: Extremely low frequency in ExAC, MAF=0.00002.; PP4: Identified in a pair of siblings with PKU. (PMID:7913581). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4).",7913581,https://erepo.genome.network/evrepo/ui/classification/CA229311/MONDO:0009861/006,False,[C/-],"NM_000277.2:c.1055delG, NC_000012.12:g.102844347del, CM000674.2:g.102844347del, NC_000012.11:g.103238125del, CM000674.1:g.103238125del, NC_000012.10:g.101762255del, NG_008690.1:g.78257del, NG_008690.2:g.119065del, NM_000277.1:c.1055del, XM_011538422.1:c.998del, NM_000277.2:c.1055del, NM_001354304.1:c.1055del, NM_000277.3:c.1055del, ENST00000307000.7:c.1040del, ENST00000549247.6:n.814del, ENST00000551114.2:n.717del, ENST00000553106.5:c.1055del, ENST00000635477.1:n.159del, ENST00000635528.1:n.570del, NM_000277.2(PAH):c.1055delG (p.Gly352Valfs)",CA229311
102475,12,102844377.0,102844377.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PVS1: Frameshift variant; PP4_Moderate: Reported in patients with PAH deficiency. Bh4 defects excluded. (PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate).",9634518,https://erepo.genome.network/evrepo/ui/classification/CA229279/MONDO:0009861/006,False,[C/-],"NM_000277.2:c.1024delG, NC_000012.12:g.102844378del, CM000674.2:g.102844378del, NC_000012.11:g.103238156del, CM000674.1:g.103238156del, NC_000012.10:g.101762286del, NG_008690.1:g.78226del, NG_008690.2:g.119034del, NM_000277.1:c.1024del, XM_011538422.1:c.967del, NM_000277.2:c.1024del, NM_001354304.1:c.1024del, NM_000277.3:c.1024del, ENST00000307000.7:c.1009del, ENST00000549247.6:n.783del, ENST00000551114.2:n.686del, ENST00000553106.5:c.1024del, ENST00000635477.1:n.128del, ENST00000635528.1:n.539del, NM_000277.2(PAH):c.1024delG (p.Ala342Hisfs)",CA229279
92752,12,102851686.0,102851686.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00006.; PVS1: Canonical +1 splice site; PP4: Detected in 5 patients with classical PKU. (PMID:8659548). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4).",8659548,https://erepo.genome.network/evrepo/ui/classification/CA220591/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.2:c.912+1G>A, NC_000012.12:g.102851686C>T, CM000674.2:g.102851686C>T, NC_000012.11:g.103245464C>T, CM000674.1:g.103245464C>T, NC_000012.10:g.101769594C>T, NG_008690.1:g.70917G>A, NG_008690.2:g.111725G>A, NM_000277.1:c.912+1G>A, XM_011538422.1:c.912+1G>A, NM_001354304.1:c.912+1G>A, NM_000277.3:c.912+1G>A, ENST00000307000.7:c.897+1G>A, ENST00000549247.6:n.671+1G>A, ENST00000551114.2:n.574+1G>A, ENST00000553106.5:c.912+1G>A, ENST00000635477.1:n.73+1G>A, NM_000277.2(PAH):c.912+1G>A",CA220591
581,12,102894756.0,102894756.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4_Moderate: Seen in multiple Chinese PKU patients. BH4 deficiency excluded. (PMID:1301187; PMID:2816939; PMID:9860305); PM3_very-strong: Detected in trans with 6 known pathogenic variants: p.R158Q; p.R241C; p.R243Q; p.E280K; p.Y356*; p.R413P (PMID:15503242, 26322415). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4_Moderate, PM3_very-strong).","9860305, 1301187, 2816939, 26322415, 15503242",https://erepo.genome.network/evrepo/ui/classification/CA251526/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.331C>T, NC_000012.12:g.102894756G>A, CM000674.2:g.102894756G>A, NC_000012.11:g.103288534G>A, CM000674.1:g.103288534G>A, NC_000012.10:g.101812664G>A, NG_008690.1:g.27847C>T, NG_008690.2:g.68655C>T, NM_000277.1:c.331C>T, XM_011538422.1:c.331C>T, NM_001354304.1:c.331C>T, XM_017019370.2:c.331C>T, NM_000277.3:c.331C>T, ENST00000307000.7:c.316C>T, ENST00000546844.1:c.331C>T, ENST00000548928.1:n.253C>T, ENST00000549111.5:n.427C>T, ENST00000550978.6:n.315C>T, ENST00000551337.5:c.331C>T, ENST00000551988.5:n.420C>T, ENST00000553106.5:c.331C>T, NM_000277.2(PAH):c.331C>T (p.Arg111Ter)",CA251526
102693,12,102866633.0,102866633.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ExAC MAF=0.00019.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.939; PS3: 2% mutant enzyme activity in BioPKU; PP4_Moderate: Detected in at least 3 patients with PAH deficiency. BH4 deficiency ruled out in 1 patient. (PMID:1307609; PMID:10429004; PMID:9634518); PM3_Strong: Detected with 3 pathogenic/likely pathogenic variants (PMID:14681498; PMID:23430918). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4_Moderate, PM3_Strong).","9634518, 1307609, 10429004, 23430918, 14681498",https://erepo.genome.network/evrepo/ui/classification/CA229570/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.472C>T, NC_000012.12:g.102866633G>A, CM000674.2:g.102866633G>A, NC_000012.11:g.103260411G>A, CM000674.1:g.103260411G>A, NC_000012.10:g.101784541G>A, NG_008690.1:g.55970C>T, NG_008690.2:g.96778C>T, NM_000277.1:c.472C>T, XM_011538422.1:c.472C>T, NM_001354304.1:c.472C>T, XM_017019370.2:c.472C>T, NM_000277.3:c.472C>T, ENST00000307000.7:c.457C>T, ENST00000549111.5:n.568C>T, ENST00000551988.5:n.530+10829C>T, ENST00000553106.5:c.472C>T, NM_000277.2(PAH):c.472C>T (p.Arg158Trp)",CA229570
102723,12,102855316.0,102855316.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF: 0.00010; PP4_Moderate: BH4 defect excluded in all patients in Liu 2015. Identified in 6 patients in this study (PMID:10394930; PMID:26600521); PM3_Strong: Identified in 6 patients, in trans with R243Q and R241C (both pathogenic) (PMID:26600521). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong).","10394930, 26600521, 26600521",https://erepo.genome.network/evrepo/ui/classification/CA275338/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.526C>T, NC_000012.12:g.102855316G>A, CM000674.2:g.102855316G>A, NC_000012.11:g.103249094G>A, CM000674.1:g.103249094G>A, NC_000012.10:g.101773224G>A, NG_008690.1:g.67287C>T, NG_008690.2:g.108095C>T, NM_000277.1:c.526C>T, XM_011538422.1:c.526C>T, NM_001354304.1:c.526C>T, XM_017019370.2:c.526C>T, NM_000277.3:c.526C>T, ENST00000307000.7:c.511C>T, ENST00000549111.5:n.622C>T, ENST00000551988.5:n.547C>T, ENST00000553106.5:c.526C>T, NM_000277.2(PAH):c.526C>T (p.Arg176Ter)",CA275338
92737,12,102894918.0,102894918.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency. ESP MAF=0.00012.; PP4_Moderate: Detected in a patient with mild HPA. Assessment of the PAH, PTS, and QDPR genes was performed. (PMID:21147011); PM3-supporting: Detected with V388M, pathogenic in ClinVar, but parental testing not performed. (PMID:21147011). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_supporting).","21147011, 21147011",https://erepo.genome.network/evrepo/ui/classification/CA220578/MONDO:0009861/006,False,[C/A/T],"NM_000277.2:c.169G>A, NC_000012.12:g.102894918C>T, CM000674.2:g.102894918C>T, NC_000012.11:g.103288696C>T, CM000674.1:g.103288696C>T, NC_000012.10:g.101812826C>T, NG_008690.1:g.27685G>A, NG_008690.2:g.68493G>A, NM_000277.1:c.169G>A, XM_011538422.1:c.169G>A, NM_001354304.1:c.169G>A, XM_017019370.2:c.169G>A, NM_000277.3:c.169G>A, ENST00000307000.7:c.154G>A, ENST00000546844.1:c.169G>A, ENST00000548677.2:n.256G>A, ENST00000548928.1:n.91G>A, ENST00000549111.5:n.265G>A, ENST00000550978.6:n.153G>A, ENST00000551337.5:c.169G>A, ENST00000551988.5:n.258G>A, ENST00000553106.5:c.169G>A, ENST00000635500.1:n.137G>A, NM_000277.2(PAH):c.169G>A (p.Glu57Lys)",CA220578
102742,12,102855261.0,102855261.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. gnomAD MAF:0.00004.; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.899; PM3_Strong: Detected in trans with V245A and R261X, both pathogenic (PMID:7981714; PMID:16601866); PP4_Moderate: Detected in 3 patients (1 HPA, 1 PKU). BH4 deficiency excluded in 2 patients. (PMID:8533759; PMID:7981714; PMID:9012412; PMID:16601866). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3_Strong, PP4_Moderate).","9012412, 16601866, 8533759, 7981714, 16601866, 7981714",https://erepo.genome.network/evrepo/ui/classification/CA229633/MONDO:0009861/006,False,[A/G],"NM_000277.2:c.581T>C, NC_000012.12:g.102855261A>G, CM000674.2:g.102855261A>G, NC_000012.11:g.103249039A>G, CM000674.1:g.103249039A>G, NC_000012.10:g.101773169A>G, NG_008690.1:g.67342T>C, NG_008690.2:g.108150T>C, NM_000277.1:c.581T>C, XM_011538422.1:c.581T>C, NM_001354304.1:c.581T>C, XM_017019370.2:c.581T>C, NM_000277.3:c.581T>C, ENST00000307000.7:c.566T>C, ENST00000549111.5:n.677T>C, ENST00000553106.5:c.581T>C, NM_000277.2(PAH):c.581T>C (p.Leu194Pro)",CA229633
92746,12,102855309.0,102855309.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. ExAC MAF=0.00017; PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.841; PS3: 39% residual phenylalanine hydroxylase activity (PMID:17935162); PP4_Moderate: Detected in 6 PKU patients. BH4 deficiency excluded. Upgraded per ClinGen PAHEP. (PMID:18294361; PMID:9634518); PM3_Strong: In trans with 3 pathogenic variants (PMID:18294361). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4_Moderate, PM3_Strong).","9634518, 18294361, 17935162, 18294361",https://erepo.genome.network/evrepo/ui/classification/CA273110/MONDO:0009861/006,False,[T/A/C],"NM_000277.2:c.533A>G, NC_000012.12:g.102855309T>C, CM000674.2:g.102855309T>C, NC_000012.11:g.103249087T>C, CM000674.1:g.103249087T>C, NC_000012.10:g.101773217T>C, NG_008690.1:g.67294A>G, NG_008690.2:g.108102A>G, NM_000277.1:c.533A>G, XM_011538422.1:c.533A>G, NM_001354304.1:c.533A>G, XM_017019370.2:c.533A>G, NM_000277.3:c.533A>G, ENST00000307000.7:c.518A>G, ENST00000549111.5:n.629A>G, ENST00000551988.5:n.554A>G, ENST00000553106.5:c.533A>G, NM_000277.2(PAH):c.533A>G (p.Glu178Gly)",CA273110
102577,12,102840473.0,102840473.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Benign,"PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01361 in ENF from gnomAD; BS2: 19 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BS2).",,https://erepo.genome.network/evrepo/ui/classification/CA200893/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.1242C>T, NC_000012.12:g.102840473G>A, CM000674.2:g.102840473G>A, NC_000012.11:g.103234251G>A, CM000674.1:g.103234251G>A, NC_000012.10:g.101758381G>A, NG_008690.1:g.82130C>T, NG_008690.2:g.122938C>T, NM_000277.1:c.1242C>T, XM_011538422.1:c.1185C>T, NM_001354304.1:c.1242C>T, NM_000277.3:c.1242C>T, ENST00000307000.7:c.1227C>T, ENST00000551114.2:n.904C>T, ENST00000553106.5:c.1242C>T, ENST00000635477.1:n.346C>T, ENST00000635528.1:n.757C>T, NM_000277.2(PAH):c.1242C>T (p.Tyr414=)",CA200893
92732,12,102840437.0,102840437.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Benign,"PAH-specific ACMG/AMP criteria applied: BA1: MAF=0.16641; BP4: no impact on gene in SIFT, Polyphen2, MutationTaster. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4).",,https://erepo.genome.network/evrepo/ui/classification/CA145978/MONDO:0009861/006,False,[A/G],"NM_000277.2:c.1278T>C, NC_000012.12:g.102840437A>G, CM000674.2:g.102840437A>G, NC_000012.11:g.103234215A>G, CM000674.1:g.103234215A>G, NC_000012.10:g.101758345A>G, NG_008690.1:g.82166T>C, NG_008690.2:g.122974T>C, NM_000277.1:c.1278T>C, XM_011538422.1:c.1221T>C, NM_001354304.1:c.1278T>C, NM_000277.3:c.1278T>C, ENST00000307000.7:c.1263T>C, ENST00000551114.2:n.940T>C, ENST00000553106.5:c.1278T>C, ENST00000635477.1:n.382T>C, ENST00000635528.1:n.793T>C, NM_000277.2(PAH):c.1278T>C (p.Asn426=)",CA145978
92741,12,102877548.0,102877548.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP3: in silico analysis supportive of damaging effect; PM3_Strong: In trans with R261Q (PMID 21147011), and in trans with IVS2+1G>A (PMID 12655554) (PMID:21147011; PMID:12655554); PP4_Moderate: BH4 deficiency excluded (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM3_Strong, PP4_Moderate).","21147011, 12655554, 21147011",https://erepo.genome.network/evrepo/ui/classification/CA220582/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.355C>T, NC_000012.12:g.102877548G>A, CM000674.2:g.102877548G>A, NC_000012.11:g.103271326G>A, CM000674.1:g.103271326G>A, NC_000012.10:g.101795456G>A, NG_008690.1:g.45055C>T, NG_008690.2:g.85863C>T, NM_000277.1:c.355C>T, XM_011538422.1:c.355C>T, NM_001354304.1:c.355C>T, XM_017019370.2:c.355C>T, NM_000277.3:c.355C>T, ENST00000307000.7:c.340C>T, ENST00000549111.5:n.451C>T, ENST00000550978.6:n.339C>T, ENST00000551337.5:c.355C>T, ENST00000551988.5:n.444C>T, ENST00000553106.5:c.355C>T, NM_000277.2(PAH):c.355C>T (p.Pro119Ser)",CA220582
306914,12,102894788.0,102894788.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: BP4: In silico overwhelmingly predict benign. REVEL = 0.553; PP4: Detected in a patient with non PKU hyperphe (PMID:11244681); PM3: H100R detected with IVS10 (PMID:11244681). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4, PM3).","11244681, 11244681",https://erepo.genome.network/evrepo/ui/classification/CA6748985/MONDO:0009861/006,False,[T/C],"NM_000277.2:c.299A>G, NC_000012.12:g.102894788T>C, CM000674.2:g.102894788T>C, NC_000012.11:g.103288566T>C, CM000674.1:g.103288566T>C, NC_000012.10:g.101812696T>C, NG_008690.1:g.27815A>G, NG_008690.2:g.68623A>G, NM_000277.1:c.299A>G, XM_011538422.1:c.299A>G, NM_001354304.1:c.299A>G, XM_017019370.2:c.299A>G, NM_000277.3:c.299A>G, ENST00000307000.7:c.284A>G, ENST00000546844.1:c.299A>G, ENST00000548928.1:n.221A>G, ENST00000549111.5:n.395A>G, ENST00000550978.6:n.283A>G, ENST00000551337.5:c.299A>G, ENST00000551988.5:n.388A>G, ENST00000553106.5:c.299A>G, NM_000277.2(PAH):c.299A>G (p.His100Arg)",CA6748985
590340,12,102852885.0,102852885.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Benign,"PAH-specific ACMG/AMP criteria applied: BS1: > PAH specific guidelines of AF-0.0002 (0.02%); BP7: No deleterious effect predicted.. In summary this variant meets criteria to be classified as likely benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7).",,https://erepo.genome.network/evrepo/ui/classification/CA6748843/MONDO:0009861/006,False,[G/A],"NM_000277.1:c.772C>T, NC_000012.12:g.102852885G>A, CM000674.2:g.102852885G>A, NC_000012.11:g.103246663G>A, CM000674.1:g.103246663G>A, NC_000012.10:g.101770793G>A, NG_008690.1:g.69718C>T, NG_008690.2:g.110526C>T, XM_011538422.1:c.772C>T, NM_000277.2:c.772C>T, NM_001354304.1:c.772C>T, NM_000277.3:c.772C>T, ENST00000307000.7:c.757C>T, ENST00000549247.6:n.531C>T, ENST00000553106.5:c.772C>T",CA6748843
102911,12,102846901.0,102846901.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Benign,"PAH-specific ACMG/AMP criteria applied: BS1: >0.02% as set by the PAH specific specifications; BP7: ; BS3_Supporting: cDNA method demonstrates 98% and intinic system demonstrates 81% residual enzyme activity; BS2: 38 homozygotes in gnomAD. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, BP7, BS3_Supporting, BS2).",,https://erepo.genome.network/evrepo/ui/classification/CA229873/MONDO:0009861/006,False,[G/A/C],"NM_000277.2:c.963C>T, NC_000012.12:g.102846901G>A, CM000674.2:g.102846901G>A, NC_000012.11:g.103240679G>A, CM000674.1:g.103240679G>A, NC_000012.10:g.101764809G>A, NG_008690.1:g.75702C>T, NG_008690.2:g.116510C>T, NM_000277.1:c.963C>T, XM_011538422.1:c.913-2470C>T, NM_001354304.1:c.963C>T, NM_000277.3:c.963C>T, ENST00000307000.7:c.948C>T, ENST00000549247.6:n.722C>T, ENST00000551114.2:n.625C>T, ENST00000553106.5:c.963C>T, ENST00000635477.1:n.74-2470C>T, ENST00000635528.1:n.478C>T, NM_000277.2(PAH):c.963C>T (p.Leu321=)",CA229873
102703,12,102866605.0,102866605.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PP4: N167S was observed in 1 case (genotype N167S/-) with benign persistent hyperphenylalaninemia (200-600 uM). (PMID:11385716); BS1: gnomAD MAF: 0.01461. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, BS1).",11385716,https://erepo.genome.network/evrepo/ui/classification/CA229585/MONDO:0009861/006,False,[T/A/C/G],"NM_000277.2:c.500A>G, NC_000012.12:g.102866605T>C, CM000674.2:g.102866605T>C, NC_000012.11:g.103260383T>C, CM000674.1:g.103260383T>C, NC_000012.10:g.101784513T>C, NG_008690.1:g.55998A>G, NG_008690.2:g.96806A>G, NM_000277.1:c.500A>G, XM_011538422.1:c.500A>G, NM_001354304.1:c.500A>G, XM_017019370.2:c.500A>G, NM_000277.3:c.500A>G, ENST00000307000.7:c.485A>G, ENST00000549111.5:n.596A>G, ENST00000551988.5:n.530+10857A>G, ENST00000553106.5:c.500A>G, NM_000277.2(PAH):c.500A>G (p.Asn167Ser)",CA229585
102687,12,102866641.0,102866641.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: absent from ExAC, gnomAD, 1000G, ESP. PAGE MAF=0.00066; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.967; PP4_Moderate: Detected in a patient with classic PKU. Cofactor deficiency excluded. (PMID:10679941); PM3: Detected in trans with R408W (P) (PMID:10679941). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3).","10679941, 10679941",https://erepo.genome.network/evrepo/ui/classification/CA229561/MONDO:0009861/006,False,[C/G/T],"NM_000277.2:c.464G>C, NC_000012.12:g.102866641C>G, CM000674.2:g.102866641C>G, NC_000012.11:g.103260419C>G, CM000674.1:g.103260419C>G, NC_000012.10:g.101784549C>G, NG_008690.1:g.55962G>C, NG_008690.2:g.96770G>C, NM_000277.1:c.464G>C, XM_011538422.1:c.464G>C, NM_001354304.1:c.464G>C, XM_017019370.2:c.464G>C, NM_000277.3:c.464G>C, ENST00000307000.7:c.449G>C, ENST00000549111.5:n.560G>C, ENST00000551988.5:n.530+10821G>C, ENST00000553106.5:c.464G>C, NM_000277.2(PAH):c.464G>C (p.Arg155Pro)",CA229561
102716,12,102855331.0,102855331.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.966; PP4_Moderate: Detected in PKU patients. BH4 deficiency assessed. Upgraded per ClinGen PAH EP. (PMID:26600521; PMID:23430918); PM3_Strong: Detected with c.611A>G (P/LP) and R408W (P). Upgraded per ClinGen SVI workgroup. (PMID:23430918; PMID:26600521). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong).","23430918, 26600521, 26600521, 23430918",https://erepo.genome.network/evrepo/ui/classification/CA229598/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.2:c.511G>A, NC_000012.12:g.102855331C>T, CM000674.2:g.102855331C>T, NC_000012.11:g.103249109C>T, CM000674.1:g.103249109C>T, NC_000012.10:g.101773239C>T, NG_008690.1:g.67272G>A, NG_008690.2:g.108080G>A, NM_000277.1:c.511G>A, XM_011538422.1:c.511G>A, NM_001354304.1:c.511G>A, XM_017019370.2:c.511G>A, NM_000277.3:c.511G>A, ENST00000307000.7:c.496G>A, ENST00000549111.5:n.607G>A, ENST00000551988.5:n.532G>A, ENST00000553106.5:c.511G>A, NM_000277.2(PAH):c.511G>A (p.Gly171Arg)",CA229598
102601,12,102912801.0,102912801.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: BS1: MAF=0.01596 in ExAC (138/8648) and 0.0104 in gnomAD (265/18868 with 3 homozygotes); PP4_moderate: Detected in multiple patients with hyperphenylalaninemia, BH4 deficiency excluded (PMID:24401910, 26322415); PM3: Detected in trans with pathogenic variant p.R243Q. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BS1, PP4_moderate, PM3).","24401910, 26322415, 24401910, 26322415",https://erepo.genome.network/evrepo/ui/classification/CA229447/MONDO:0009861/006,False,[C/T],"NM_000277.2:c.158G>A, NC_000012.12:g.102912801C>T, CM000674.2:g.102912801C>T, NC_000012.11:g.103306579C>T, CM000674.1:g.103306579C>T, NC_000012.10:g.101830709C>T, NG_008690.1:g.9802G>A, NG_008690.2:g.50610G>A, NM_000277.1:c.158G>A, XM_011538422.1:c.158G>A, NM_001354304.1:c.158G>A, XM_017019370.2:c.158G>A, NM_000277.3:c.158G>A, ENST00000307000.7:c.143G>A, ENST00000546844.1:c.158G>A, ENST00000548677.2:n.245G>A, ENST00000548928.1:n.80G>A, ENST00000549111.5:n.254G>A, ENST00000550978.6:n.142G>A, ENST00000551337.5:c.158G>A, ENST00000551988.5:n.247G>A, ENST00000553106.5:c.158G>A, ENST00000635500.1:n.126G>A, NM_000277.2(PAH):c.158G>A (p.Arg53His)",CA229447
102729,12,102855307.0,102855307.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Deleterious effect predicted in SIFT, Polyphen-2, MutationTaster. REVEL=0.929; PP4_Moderate: Detected in 1 PKU patient, primary BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:23430918); PM3: Detected with c.1066-11G>A (P) (PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3).","23430918, 23430918",https://erepo.genome.network/evrepo/ui/classification/CA229613/MONDO:0009861/006,False,[A/G/T],"NM_000277.2:c.535T>A, NC_000012.12:g.102855307A>T, CM000674.2:g.102855307A>T, NC_000012.11:g.103249085A>T, CM000674.1:g.103249085A>T, NC_000012.10:g.101773215A>T, NG_008690.1:g.67296T>A, NG_008690.2:g.108104T>A, NM_000277.1:c.535T>A, XM_011538422.1:c.535T>A, NM_001354304.1:c.535T>A, XM_017019370.2:c.535T>A, NM_000277.3:c.535T>A, ENST00000307000.7:c.520T>A, ENST00000549111.5:n.631T>A, ENST00000551988.5:n.556T>A, ENST00000553106.5:c.535T>A, NM_000277.2(PAH):c.535T>A (p.Tyr179Asn)",CA229613
102871,12,102852812.0,102852812.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in gnomAD+ExAC (MAF=0.00006). Absent from 1000G, ESP.; PP4_Moderate: Detected in Costa Rican and 1 Spanish PKU patients, exclusion of defects in tetrahydrobiopterine metabolism. (PMID:8860005; PMID:8981952); PM3_Strong: Detected in trans with I269L and R408W, known pathogenic variants. (PMID:9521426; PMID:23430918). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).","8860005, 8981952, 9521426, 23430918",https://erepo.genome.network/evrepo/ui/classification/CA229814/MONDO:0009861/006,False,[C/G],"NM_000277.2:c.842+3G>C, NC_000012.12:g.102852812C>G, CM000674.2:g.102852812C>G, NC_000012.11:g.103246590C>G, CM000674.1:g.103246590C>G, NC_000012.10:g.101770720C>G, NG_008690.1:g.69791G>C, NG_008690.2:g.110599G>C, NM_000277.1:c.842+3G>C, XM_011538422.1:c.842+3G>C, NM_001354304.1:c.842+3G>C, NM_000277.3:c.842+3G>C, ENST00000307000.7:c.827+3G>C, ENST00000549247.6:n.601+3G>C, ENST00000553106.5:c.842+3G>C, ENST00000635477.1:n.3+3G>C, NM_000277.2(PAH):c.842+3G>C",CA229814
92743,12,102866605.0,102866605.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (MAF=0.00003). Absent from gnomAD, 1000G, ESP; PP4_Moderate: Found in a French patient with HPA and 2 unrelated UK patients. BH4 deficiencies not assessed/reported. Seen in 1 German patient, Cofactor deficiency was excluded by the BH4 test. 1 Spanish patient, a defect in the synthesis or regeneration pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels and measuring dihydropteridine reductase activity. (PMID:26666653; PMID:9012412; PMID:10679941); PM3_Strong: Patient 664 with genotype N167I/Rl58Q (Pathogenic in ClinVar). Detected with G272X and R408W, known pathogenic variants. (PMID:24368688; PMID:26666653). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).","9012412, 10679941, 26666653, 24368688, 26666653",https://erepo.genome.network/evrepo/ui/classification/CA220584/MONDO:0009861/006,False,[T/A/C/G],"NM_000277.2:c.500A>T, NC_000012.12:g.102866605T>A, CM000674.2:g.102866605T>A, NC_000012.11:g.103260383T>A, CM000674.1:g.103260383T>A, NC_000012.10:g.101784513T>A, NG_008690.1:g.55998A>T, NG_008690.2:g.96806A>T, NM_000277.1:c.500A>T, XM_011538422.1:c.500A>T, NM_001354304.1:c.500A>T, XM_017019370.2:c.500A>T, NM_000277.3:c.500A>T, ENST00000307000.7:c.485A>T, ENST00000549111.5:n.596A>T, ENST00000551988.5:n.530+10857A>T, ENST00000553106.5:c.500A>T, NM_000277.2(PAH):c.500A>T (p.Asn167Ile)",CA220584
102706,12,102866599.0,102866599.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: This variant has been reported in multiple mild hyperphenylalaninaemia (MHP) patients, with BH4 defects excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:10234516); PM3_Strong: Detected with P281L and A403V, both pathogenic variants (PMID:10234516). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_Strong).","10234516, 10234516",https://erepo.genome.network/evrepo/ui/classification/CA286505/MONDO:0009861/006,False,[C/G/T],"NM_000277.2:c.506G>A, NC_000012.12:g.102866599C>T, CM000674.2:g.102866599C>T, NC_000012.11:g.103260377C>T, CM000674.1:g.103260377C>T, NC_000012.10:g.101784507C>T, NG_008690.1:g.56004G>A, NG_008690.2:g.96812G>A, NM_000277.1:c.506G>A, XM_011538422.1:c.506G>A, NM_001354304.1:c.506G>A, XM_017019370.2:c.506G>A, NM_000277.3:c.506G>A, ENST00000307000.7:c.491G>A, ENST00000549111.5:n.602G>A, ENST00000551988.5:n.530+10863G>A, ENST00000553106.5:c.506G>A, NM_000277.2(PAH):c.506G>A (p.Arg169His)",CA286505
120273,12,102894737.0,102894737.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC& gnomAD (MAF 0.00018). Absent from 1000G, ESP. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2).",,https://erepo.genome.network/evrepo/ui/classification/CA267651/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.350C>T, NC_000012.12:g.102894737G>A, CM000674.2:g.102894737G>A, NC_000012.11:g.103288515G>A, CM000674.1:g.103288515G>A, NC_000012.10:g.101812645G>A, NG_008690.1:g.27866C>T, NG_008690.2:g.68674C>T, NM_000277.1:c.350C>T, XM_011538422.1:c.350C>T, NM_001354304.1:c.350C>T, XM_017019370.2:c.350C>T, NM_000277.3:c.350C>T, ENST00000307000.7:c.335C>T, ENST00000546844.1:c.350C>T, ENST00000548928.1:n.272C>T, ENST00000549111.5:n.446C>T, ENST00000550978.6:n.334C>T, ENST00000551337.5:c.350C>T, ENST00000551988.5:n.439C>T, ENST00000553106.5:c.350C>T, NM_000277.2(PAH):c.350C>T (p.Thr117Ile)",CA267651
92729,12,102843777.0,102843777.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: gnomAD MAF 0.00017; PP4_Moderate: Detected in PKU patients (PMID:25894915); PM3_Strong: in trans with p.W326X (Pathogenic), and IVS4-1G>A (Pathogenic). (PMID:25894915). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate, PM3_Strong).","25894915, 25894915",https://erepo.genome.network/evrepo/ui/classification/CA273107/MONDO:0009861/006,False,[G/A/C/T],"NM_000277.2:c.1068C>A, NC_000012.12:g.102843777G>T, CM000674.2:g.102843777G>T, NC_000012.11:g.103237555G>T, CM000674.1:g.103237555G>T, NC_000012.10:g.101761685G>T, NG_008690.1:g.78826C>A, NG_008690.2:g.119634C>A, NM_000277.1:c.1068C>A, XM_011538422.1:c.1011C>A, NM_001354304.1:c.1068C>A, NM_000277.3:c.1068C>A, ENST00000307000.7:c.1053C>A, ENST00000549247.6:n.827C>A, ENST00000551114.2:n.730C>A, ENST00000553106.5:c.1068C>A, ENST00000635477.1:n.172C>A, ENST00000635528.1:n.583C>A, NM_000277.2(PAH):c.1068C>A (p.Tyr356Ter)",CA273107
598,12,102852839.0,102852839.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC and gnomAD (1 allele); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.978; PP4_Moderate: S273F was detected in in Northern Ireland, Belgium/French, Western Scotland, and New South Wales PKU patients. BH4 deficiency was assessed in 1 study. Upgraded per ClinGen Metabolic workgroup. (PMID:1671881; PMID:8533759; PMID:9012412; PMID:24368688); PM3_Strong: Seen with 2 known pathogenic mutations: I65T, R408W. Upgraded based on SVI worgroup recommendations and approved PAH guidelines (PMID:24368688). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong).","1671881, 24368688, 9012412, 8533759, 24368688",https://erepo.genome.network/evrepo/ui/classification/CA229785/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.818C>T, NC_000012.12:g.102852839G>A, CM000674.2:g.102852839G>A, NC_000012.11:g.103246617G>A, CM000674.1:g.103246617G>A, NC_000012.10:g.101770747G>A, NG_008690.1:g.69764C>T, NG_008690.2:g.110572C>T, NM_000277.1:c.818C>T, XM_011538422.1:c.818C>T, NM_001354304.1:c.818C>T, NM_000277.3:c.818C>T, ENST00000307000.7:c.803C>T, ENST00000549247.6:n.577C>T, ENST00000553106.5:c.818C>T, NM_000277.2(PAH):c.818C>T (p.Ser273Phe)",CA229785
636,12,102894893.0,102894893.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM3_VeryStrong: Detected with Y414C (P), R408W (P), P281L (P), IVS10nt-11 (P), R252W (P/LP), and R243Q(P). (PMID:12501224; PMID:1301201; PMID:10767174); PP3: Predicted dleterious in SIZFT, Polyphen2, MutationTaster. REVEL=0.985; PP4_Moderate: Detected in a patient with mild PKU. BH4 deficiency excluded. Upgraded per ClinGen PAH EP. (PMID:12501224); PS3: 25% mutant enzyme activity in COS cells as compared in wt (PMID:1301201). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_VeryStrong, PP3, PP4_Moderate, PS3).","12501224, 21871829, 10767174, 1301201, 12501224, 1301201",https://erepo.genome.network/evrepo/ui/classification/CA251544/MONDO:0009861/006,True,[A/C/G/T],"NM_000277.2:c.194T>C, NC_000012.12:g.102894893A>G, CM000674.2:g.102894893A>G, NC_000012.11:g.103288671A>G, CM000674.1:g.103288671A>G, NC_000012.10:g.101812801A>G, NG_008690.1:g.27710T>C, NG_008690.2:g.68518T>C, NM_000277.1:c.194T>C, XM_011538422.1:c.194T>C, NM_001354304.1:c.194T>C, XM_017019370.2:c.194T>C, NM_000277.3:c.194T>C, ENST00000307000.7:c.179T>C, ENST00000546844.1:c.194T>C, ENST00000548677.2:n.281T>C, ENST00000548928.1:n.116T>C, ENST00000549111.5:n.290T>C, ENST00000550978.6:n.178T>C, ENST00000551337.5:c.194T>C, ENST00000551988.5:n.283T>C, ENST00000553106.5:c.194T>C, ENST00000635500.1:n.162T>C, NM_000277.2(PAH):c.194T>C (p.Ile65Thr)",CA251544
120287,12,102852845.0,102852845.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.957; PP4_Moderate: H271L seen in a Chinese PKU patient. BH4 deficiencies excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate).",26503515,https://erepo.genome.network/evrepo/ui/classification/CA267675/MONDO:0009861/006,False,[T/A/C],"NM_000277.2:c.812A>T, NC_000012.12:g.102852845T>A, CM000674.2:g.102852845T>A, NC_000012.11:g.103246623T>A, CM000674.1:g.103246623T>A, NC_000012.10:g.101770753T>A, NG_008690.1:g.69758A>T, NG_008690.2:g.110566A>T, NM_000277.1:c.812A>T, XM_011538422.1:c.812A>T, NM_001354304.1:c.812A>T, NM_000277.3:c.812A>T, ENST00000307000.7:c.797A>T, ENST00000549247.6:n.571A>T, ENST00000553106.5:c.812A>T, NM_000277.2(PAH):c.812A>T (p.His271Leu)",CA267675
92740,12,102894769.0,102894777.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Identified a single time in gnomAD (4.06e-06) and absent in ExAC; PM4: p.Ala104_Val106del; PP4: Single patient picked up on NBS with no confirmation studies, no clinical info, no Phe levels, etc. (PMID:27308838). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4, PP4).",27308838,https://erepo.genome.network/evrepo/ui/classification/CA220580/MONDO:0009861/006,False,[GACAGTGGC/-],"NM_000277.2:c.310_318delGCCACTGTC, NC_000012.12:g.102894769_102894777del, CM000674.2:g.102894769_102894777del, NC_000012.11:g.103288547_103288555del, CM000674.1:g.103288547_103288555del, NC_000012.10:g.101812677_101812685del, NG_008690.1:g.27826_27834del, NG_008690.2:g.68634_68642del, NM_000277.1:c.310_318del, XM_011538422.1:c.310_318del, NM_000277.2:c.310_318del, NM_001354304.1:c.310_318del, XM_017019370.2:c.310_318del, NM_000277.3:c.310_318del, ENST00000307000.7:c.295_303del, ENST00000546844.1:c.310_318del, ENST00000548928.1:n.232_240del, ENST00000549111.5:n.406_414del, ENST00000550978.6:n.294_302del, ENST00000551337.5:c.310_318del, ENST00000551988.5:n.399_407del, ENST00000553106.5:c.310_318del, NM_000277.2(PAH):c.310_318delGCCACTGTC (p.Ala104_Val106del)",CA220580
120271,12,102894875.0,102894876.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: chr12-103288654--GAGAAG; Absent from population databases; PM4: in-frame insertion. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4).",,https://erepo.genome.network/evrepo/ui/classification/CA267647/MONDO:0009861/006,False,[-/AGAAGG],"NM_000277.2:c.205_210dup, NM_000277.1:c.206_211dup, XM_011538422.1:c.206_211dup, NM_000277.2:c.206_211dup, NM_001354304.1:c.206_211dup, XM_017019370.2:c.206_211dup, NM_000277.3:c.206_211dup, ENST00000307000.7:c.191_196dup, ENST00000546844.1:c.206_211dup, ENST00000548677.2:n.293_298dup, ENST00000548928.1:n.128_133dup, ENST00000549111.5:n.302_307dup, ENST00000550978.6:n.190_195dup, ENST00000551337.5:c.206_211dup, ENST00000551988.5:n.295_300dup, ENST00000553106.5:c.206_211dup, ENST00000635500.1:n.174_179dup, NC_000012.12:g.102894877_102894882dup, CM000674.2:g.102894877_102894882dup, NC_000012.11:g.103288655_103288660dup, CM000674.1:g.103288655_103288660dup, NC_000012.10:g.101812785_101812790dup, NG_008690.1:g.27722_27727dup, NG_008690.2:g.68530_68535dup, NM_000277.2(PAH):c.205_210dup (p.Ser70_Arg71insProSer)",CA267647
225135,12,102852857.0,102852857.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD ( 0.00001, 0.000004063); PP3: Predicted deleterious in SIFT, Polyphen2, MutationTaster. REVEL=0.975; PP4_Moderate: Q267L found in 1 Japanese PKU allele and in 1 Chinese PKU patient. Analysis of dihydropteridine reductase activity in red blood cells, biopterin loading test and/or pteridine analysis in urine was performed in the Japanese study. Upgraded per ClinGen Metabolic workgroup. (PMID:21307867; PMID:24078561; PMID:26503515). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate).","21307867, 26503515, 24078561",https://erepo.genome.network/evrepo/ui/classification/CA354145/MONDO:0009861/006,False,[T/A/C],"NM_000277.2:c.800A>T, NC_000012.12:g.102852857T>A, CM000674.2:g.102852857T>A, NC_000012.11:g.103246635T>A, CM000674.1:g.103246635T>A, NC_000012.10:g.101770765T>A, NG_008690.1:g.69746A>T, NG_008690.2:g.110554A>T, NM_000277.1:c.800A>T, XM_011538422.1:c.800A>T, NM_001354304.1:c.800A>T, NM_000277.3:c.800A>T, ENST00000307000.7:c.785A>T, ENST00000549247.6:n.559A>T, ENST00000553106.5:c.800A>T, NM_000277.2(PAH):c.800A>T (p.Gln267Leu)",CA354145
102821,12,102852912.0,102852912.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extremely low frequency in ExAC and gnomAD (0.00004065); PP3: Deleterious effect predicted in SIFT, Polyphen2, MutationTaster. REVEL=0.981; PP4_Moderate: L249F was seen 3 times in HPA patients associated with 2 different haplotypes. DHPR defeciency was excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:8533759); PM3_VeryStrong: Seen with R261X, A309V, V388M, R261Q. All Pathogenic/Likely Pathogenic in ClinVar. Upgraded per ClinGen SVI Workgroup (PMID:21871829; PMID:24765287). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_VeryStrong).","8533759, 24765287, 21871829",https://erepo.genome.network/evrepo/ui/classification/CA273356/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.745C>T, NC_000012.12:g.102852912G>A, CM000674.2:g.102852912G>A, NC_000012.11:g.103246690G>A, CM000674.1:g.103246690G>A, NC_000012.10:g.101770820G>A, NG_008690.1:g.69691C>T, NG_008690.2:g.110499C>T, NM_000277.1:c.745C>T, XM_011538422.1:c.745C>T, NM_001354304.1:c.745C>T, NM_000277.3:c.745C>T, ENST00000307000.7:c.730C>T, ENST00000549247.6:n.504C>T, ENST00000553106.5:c.745C>T, NM_000277.2(PAH):c.745C>T (p.Leu249Phe)",CA273356
102795,12,102852957.0,102852957.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Benign,"PAH-specific ACMG/AMP criteria applied: BA1: Highest MAF=0.10514 in 1000G. 35 homozygotes in ExAC; BP4: HSF: No significant splicing motif alteration detected. This mutation has probably no impact on splicing. CADD=1.163344. In summary this variant meets criteria to be classified as benign for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BA1, BP4).",,https://erepo.genome.network/evrepo/ui/classification/CA180267/MONDO:0009861/006,False,[T/A],"NM_000277.2:c.707-7A>T, NC_000012.12:g.102852957T>A, CM000674.2:g.102852957T>A, NC_000012.11:g.103246735T>A, CM000674.1:g.103246735T>A, NC_000012.10:g.101770865T>A, NG_008690.1:g.69646A>T, NG_008690.2:g.110454A>T, NM_000277.1:c.707-7A>T, XM_011538422.1:c.707-7A>T, NM_001354304.1:c.707-7A>T, NM_000277.3:c.707-7A>T, ENST00000307000.7:c.692-7A>T, ENST00000549247.6:n.459A>T, ENST00000553106.5:c.707-7A>T, NM_000277.2(PAH):c.707-7A>T",CA180267
603,12,102852828.0,102852828.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.829T>G (p.Tyr277Asp) variant in PAH has been reported in 2 individuals with Classic PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925; PMID: 23500595). This variant has an extremely low allele frequency (1/121400) in ExAC (PM2; http://exac.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org/centralStore/biopku/PAH%20activity.pdf). This variant was detected in trans with L48S (Pathogenic in ClinVar) (PM3; PMID: 23500595). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3","23500595, 8268925, 23500595",https://erepo.genome.network/evrepo/ui/classification/CA251534/MONDO:0009861/006,False,[A/C],"NM_000277.2:c.829T>G, NC_000012.12:g.102852828A>C, CM000674.2:g.102852828A>C, NC_000012.11:g.103246606A>C, CM000674.1:g.103246606A>C, NC_000012.10:g.101770736A>C, NG_008690.1:g.69775T>G, NG_008690.2:g.110583T>G, NM_000277.1:c.829T>G, XM_011538422.1:c.829T>G, NM_001354304.1:c.829T>G, NM_000277.3:c.829T>G, ENST00000307000.7:c.814T>G, ENST00000549247.6:n.588T>G, ENST00000553106.5:c.829T>G, NM_000277.2(PAH):c.829T>G (p.Tyr277Asp)",CA251534
92748,12,102852922.0,102852922.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Benign,"The c.735G>A (p.Val245=) variant in PAH has a MAF of 0.29058 in ExAC (BA1; http://exac.broadinstitute.org) with 6,524 homozygotes (BS2). This is a synonymous variant, predicted tolerated and benign in SIFT, Polyphen. MutationTaster predicted polymorphism with no abrogation of splice sites (BP4). In summary, this variant meets criteria to be classified as benign.",,https://erepo.genome.network/evrepo/ui/classification/CA145982/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.2:c.735G>A, NC_000012.12:g.102852922C>T, CM000674.2:g.102852922C>T, NC_000012.11:g.103246700C>T, CM000674.1:g.103246700C>T, NC_000012.10:g.101770830C>T, NG_008690.1:g.69681G>A, NG_008690.2:g.110489G>A, NM_000277.1:c.735G>A, XM_011538422.1:c.735G>A, NM_001354304.1:c.735G>A, NM_000277.3:c.735G>A, ENST00000307000.7:c.720G>A, ENST00000549247.6:n.494G>A, ENST00000553106.5:c.735G>A, NM_000277.2(PAH):c.735G>A (p.Val245=)",CA145982
599,12,102852814.0,102852814.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Canonical +1 splice site; PM2: gnomAD MAF 0.00008; PP4: Reported in 3 PKU populations: Slovak, Germany, Italy (PMID:1671810; PMID:10394930; PMID:23764561); PM3: (PMID:20188615; PMID:24941924). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4, PM3).","23764561, 10394930, 1671810, 24941924, 20188615",https://erepo.genome.network/evrepo/ui/classification/CA229811/MONDO:0009861/006,False,[C/A/T],"NM_000277.2:c.842+1G>A, NC_000012.12:g.102852814C>T, CM000674.2:g.102852814C>T, NC_000012.11:g.103246592C>T, CM000674.1:g.103246592C>T, NC_000012.10:g.101770722C>T, NG_008690.1:g.69789G>A, NG_008690.2:g.110597G>A, NM_000277.1:c.842+1G>A, XM_011538422.1:c.842+1G>A, NM_001354304.1:c.842+1G>A, NM_000277.3:c.842+1G>A, ENST00000307000.7:c.827+1G>A, ENST00000549247.6:n.601+1G>A, ENST00000553106.5:c.842+1G>A, ENST00000635477.1:n.3+1G>A, NM_000277.2(PAH):c.842+1G>A",CA229811
632,12,102852923.0,102852923.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM5: V245L Pathogenic; PP4_Moderate: Seen in at least 7 MHP patients. Exclusion of a defect in tetrahydrobiopterin metabolism. Upgraded per ClinGen Metabolic Workgroup. (PMID:7981714; PMID:9298832; PMID:9634518); PM3_VeryStrong: V245A detected with IVS-12nt1, R252W, L194P (both P/LP), R408W (Path). Upgraded per ClinGen SVI Workgroup (PMID:7981714; PMID:9298832; PMID:8088845). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP4_Moderate, PM3_VeryStrong).","9634518, 7981714, 9298832, 7981714, 9298832, 8088845, 11161839",https://erepo.genome.network/evrepo/ui/classification/CA114372/MONDO:0009861/006,False,[A/G/T],"NM_000277.2:c.734T>C, NC_000012.12:g.102852923A>G, CM000674.2:g.102852923A>G, NC_000012.11:g.103246701A>G, CM000674.1:g.103246701A>G, NC_000012.10:g.101770831A>G, NG_008690.1:g.69680T>C, NG_008690.2:g.110488T>C, NM_000277.1:c.734T>C, XM_011538422.1:c.734T>C, NM_001354304.1:c.734T>C, NM_000277.3:c.734T>C, ENST00000307000.7:c.719T>C, ENST00000549247.6:n.493T>C, ENST00000553106.5:c.734T>C, NM_000277.2(PAH):c.734T>C (p.Val245Ala)",CA114372
102483,12,102844368.0,102844368.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from controls in ExaC, 100 Genomes, ESP, and gnomAD; PP3: Deleterious effected predicted by SIFT, Polyphen2, and MutationTaster; PM5: A345S (Variant ID 102484) predicted pathogenic in ClinVar; PP4_Moderate: Found in two individuals with Classic PKU on exon 10.Urinary pterin analysis and dihydropteridine reductase (DHPR) assay were performed t (PMID:15503242); PM3: Found in trans with R243Q (pathogenic in ClinVar). (PMID:15503242). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3).","15503242, 15503242",https://erepo.genome.network/evrepo/ui/classification/CA229291/MONDO:0009861/006,False,[C/A/T],"NM_000277.2:c.1033G>A, NC_000012.12:g.102844368C>T, CM000674.2:g.102844368C>T, NC_000012.11:g.103238146C>T, CM000674.1:g.103238146C>T, NC_000012.10:g.101762276C>T, NG_008690.1:g.78235G>A, NG_008690.2:g.119043G>A, NM_000277.1:c.1033G>A, XM_011538422.1:c.976G>A, NM_001354304.1:c.1033G>A, NM_000277.3:c.1033G>A, ENST00000307000.7:c.1018G>A, ENST00000549247.6:n.792G>A, ENST00000551114.2:n.695G>A, ENST00000553106.5:c.1033G>A, ENST00000635477.1:n.137G>A, ENST00000635528.1:n.548G>A, NM_000277.2(PAH):c.1033G>A (p.Ala345Thr)",CA229291
102557,12,102843645.0,102843645.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: 8.1e-6 allele frequency in GnomAD, not found in any other databases; PM3: [c.898G>T];[c.1199+1G>C] in a patient with mild hyperphe (180umol/L); PP4_Moderate: Single patient in Sterl 2013, BH4 defect excluded. Also identified in multiple other patients (7 publications linked through ClinVar) (PMID:22526846); PVS1: +1 canonical splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM3, PP4_Moderate, PVS1).",22526846,https://erepo.genome.network/evrepo/ui/classification/CA274088/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.2:c.1199+1G>C, NC_000012.12:g.102843645C>G, CM000674.2:g.102843645C>G, NC_000012.11:g.103237423C>G, CM000674.1:g.103237423C>G, NC_000012.10:g.101761553C>G, NG_008690.1:g.78958G>C, NG_008690.2:g.119766G>C, NM_000277.1:c.1199+1G>C, XM_011538422.1:c.1142+1G>C, NM_001354304.1:c.1199+1G>C, NM_000277.3:c.1199+1G>C, ENST00000307000.7:c.1184+1G>C, ENST00000549247.6:n.958+1G>C, ENST00000551114.2:n.861+1G>C, ENST00000553106.5:c.1199+1G>C, ENST00000635477.1:n.303+1G>C, ENST00000635528.1:n.714+1G>C, NM_000277.2(PAH):c.1199+1G>C",CA274088
102696,12,102917083.0,102917084.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: ExAC:8.238e-06; gnomAD:0.000004062; 1000G + ESP: absent; PVS1: Null variant- frameshift. Subject to nonsense mediated decay.; PM3: found in trans with L48S (VarID608, Pathogenic) (PMID:8535445); PP4: 47delCT found in 1 patient with moderate PKU. BH4 deficiency not ruled out. (PMID:8535445). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PM3, PP4).","8535445, 8535445",https://erepo.genome.network/evrepo/ui/classification/CA229574/MONDO:0009861/006,False,[AG/-],"NM_000277.2:c.47_48delCT, NC_000012.12:g.102917087_102917088del, CM000674.2:g.102917087_102917088del, NC_000012.11:g.103310865_103310866del, CM000674.1:g.103310865_103310866del, NC_000012.10:g.101834995_101834996del, NG_008690.1:g.5519_5520del, NG_008690.2:g.46327_46328del, NM_000277.1:c.47_48del, XM_011538422.1:c.47_48del, NM_000277.2:c.47_48del, NM_001354304.1:c.47_48del, XM_017019370.2:c.47_48del, NM_000277.3:c.47_48del, ENST00000307000.7:c.-101_-100del, ENST00000546844.1:c.47_48del, ENST00000547319.1:n.358_359del, ENST00000549111.5:n.143_144del, ENST00000550978.6:n.31_32del, ENST00000551337.5:c.47_48del, ENST00000551988.5:n.136_137del, ENST00000553106.5:c.47_48del, ENST00000635500.1:n.29-4186_29-4185del, NM_000277.2(PAH):c.47_48delCT (p.Ser16Terfs)",CA229574
102913,12,102846895.0,102846897.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in gnomAD: 0.000008131; PM4: Protein length change as a results of in-frame deletion; PP4_Moderate: T323del found in 2 PKU patients. BH4 deficiency excluded. Upgraded per ClinGen Metabolic workgroup. (PMID:21147011); PM3_Strong: T323del detected with P281 in 1 PKU patient, and L48S in another PKU patient. Both pathogenic. Upgraded per ClinGen SVI Workgroup. (PMID:21147011). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PM4, PP4_Moderate, PM3_Strong).","21147011, 21147011",https://erepo.genome.network/evrepo/ui/classification/CA229876/MONDO:0009861/006,False,[TGT/-],"NM_000277.1:c.967_969delACA, NC_000012.12:g.102846895_102846897del, CM000674.2:g.102846895_102846897del, NC_000012.11:g.103240673_103240675del, CM000674.1:g.103240673_103240675del, NC_000012.10:g.101764803_101764805del, NG_008690.1:g.75706_75708del, NG_008690.2:g.116514_116516del, NM_000277.1:c.967_969del, XM_011538422.1:c.913-2466_913-2464del, NM_000277.2:c.967_969del, NM_001354304.1:c.967_969del, NM_000277.3:c.967_969del, ENST00000307000.7:c.952_954del, ENST00000549247.6:n.726_728del, ENST00000551114.2:n.629_631del, ENST00000553106.5:c.967_969del, ENST00000635477.1:n.74-2466_74-2464del, ENST00000635528.1:n.482_484del, NM_000277.1(PAH):c.967_969delACA (p.Thr323del)",CA229876
281073,12,102844418.0,102844418.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP3: Predicted deleterious in SIFT, PolyPhen2, Mutation Taster. REVEL=0.952. In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3).",,https://erepo.genome.network/evrepo/ui/classification/CA10603804/MONDO:0009861/006,False,[G/A/T],"NM_000277.1:c.983C>T, NC_000012.12:g.102844418G>A, CM000674.2:g.102844418G>A, NC_000012.11:g.103238196G>A, CM000674.1:g.103238196G>A, NC_000012.10:g.101762326G>A, NG_008690.1:g.78185C>T, NG_008690.2:g.118993C>T, XM_011538422.1:c.926C>T, NM_000277.2:c.983C>T, NM_001354304.1:c.983C>T, NM_000277.3:c.983C>T, ENST00000307000.7:c.968C>T, ENST00000549247.6:n.742C>T, ENST00000551114.2:n.645C>T, ENST00000553106.5:c.983C>T, ENST00000635477.1:n.87C>T, ENST00000635528.1:n.498C>T, NM_000277.1(PAH):c.983C>T (p.Thr328Ile)",CA10603804
439228,12,102852811.0,102852811.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP3: HSF: Broken WT Donor Site, New Donor Site. MaxEnt: Broken WT Donor Site.; PM2: Absent from ExAC, gnomAD, 1000G, ESP; PP4_Moderate: IVS7+4A>G seen in 2 PKU patients. BH4 deficiency was ruled out. Upgraded per ClinGen PAH EP. (PMID:21147011); PM3: Detected in trans with A300S, pathogenic in ClinVar (PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PM2, PP4_Moderate, PM3).","21147011, 21147011",https://erepo.genome.network/evrepo/ui/classification/CA16020870/MONDO:0009861/006,False,[T/A/C],"NM_000277.1:c.842+4A>G, NC_000012.12:g.102852811T>C, CM000674.2:g.102852811T>C, NC_000012.11:g.103246589T>C, CM000674.1:g.103246589T>C, NC_000012.10:g.101770719T>C, NG_008690.1:g.69792A>G, NG_008690.2:g.110600A>G, XM_011538422.1:c.842+4A>G, NM_000277.2:c.842+4A>G, NM_001354304.1:c.842+4A>G, NM_000277.3:c.842+4A>G, ENST00000307000.7:c.827+4A>G, ENST00000549247.6:n.601+4A>G, ENST00000553106.5:c.842+4A>G, ENST00000635477.1:n.3+4A>G",CA16020870
92742,12,102877457.0,102877457.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.441+5G>T variant in PAH has been reported on >17 PKU alleles (BH4 deficiency excluded). (PP4_Moderate; PMID: 17935162; PMID: 23514811). This variant has an extremely low allele frequency (0.00002886) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 0% enzyme activity (PS3; http://www.biopku.org). This variant was detected in trans with IVS10-11g>a and p.V388M (Pathogenic in ClinVar) (PM3_Strong; PMID: 23514811). Computational prediction tools and conservation analysis suggest that the c.441+5G>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Strong","17935162, 23514811, 23514811",https://erepo.genome.network/evrepo/ui/classification/CA273112/MONDO:0009861/006,False,[C/A/T],"NM_000277.1:c.441+5G>T, NC_000012.12:g.102877457C>A, CM000674.2:g.102877457C>A, NC_000012.11:g.103271235C>A, CM000674.1:g.103271235C>A, NC_000012.10:g.101795365C>A, NG_008690.1:g.45146G>T, NG_008690.2:g.85954G>T, XM_011538422.1:c.441+5G>T, NM_000277.2:c.441+5G>T, NM_001354304.1:c.441+5G>T, XM_017019370.2:c.441+5G>T, NM_000277.3:c.441+5G>T, ENST00000307000.7:c.426+5G>T, ENST00000549111.5:n.537+5G>T, ENST00000550978.6:n.430G>T, ENST00000551988.5:n.530+5G>T, ENST00000553106.5:c.441+5G>T, NM_000277.1(PAH):c.441+5G>T",CA273112
577,12,102840493.0,102840493.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP3: ; PS3: PMID 17935162: Table 1: p.Arg408Trp 1.85% WT activity PMID 25596310: 1.3% activity of WT (Table S4) (PMID:25596310; PMID:17935162); PP4_Moderate: most common PAH mutation in cohort; exclude BH4 deficiency. (PMID:25596310; PMID:9634518); PM3_Strong: Detected with IVS12+1G>A, M1V (Pathogenic/LP) (PMID:9634518; PMID:1971147; PMID:1609797). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PP4_Moderate, PM3_Strong).","9634518, 25596310, 25596310, 17935162, 1971147, 9634518, 1609797",https://erepo.genome.network/evrepo/ui/classification/CA251523/MONDO:0009861/006,False,[G/A],"NM_000277.1:c.1222C>T, NC_000012.12:g.102840493G>A, CM000674.2:g.102840493G>A, NC_000012.11:g.103234271G>A, CM000674.1:g.103234271G>A, NC_000012.10:g.101758401G>A, NG_008690.1:g.82110C>T, NG_008690.2:g.122918C>T, XM_011538422.1:c.1165C>T, NM_000277.2:c.1222C>T, NM_001354304.1:c.1222C>T, NM_000277.3:c.1222C>T, ENST00000307000.7:c.1207C>T, ENST00000551114.2:n.884C>T, ENST00000553106.5:c.1222C>T, ENST00000635477.1:n.326C>T, ENST00000635528.1:n.737C>T, NM_000277.1(PAH):c.1222C>T (p.Arg408Trp)",CA251523
596,12,102852843.0,102852843.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Absent from 1000G, ESP. Extrememly low frequency in ExAC, gnomAD (MAF= 0.00006, 0.0003093); PVS1: Nonsense variant. Predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.; PP4: G272X found on one allele of a patient with classic PKU (PMID:1975559). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4).",1975559,https://erepo.genome.network/evrepo/ui/classification/CA251532/MONDO:0009861/006,False,[C/A],"NM_000277.1:c.814G>T, NC_000012.12:g.102852843C>A, CM000674.2:g.102852843C>A, NC_000012.11:g.103246621C>A, CM000674.1:g.103246621C>A, NC_000012.10:g.101770751C>A, NG_008690.1:g.69760G>T, NG_008690.2:g.110568G>T, XM_011538422.1:c.814G>T, NM_000277.2:c.814G>T, NM_001354304.1:c.814G>T, NM_000277.3:c.814G>T, ENST00000307000.7:c.799G>T, ENST00000549247.6:n.573G>T, ENST00000553106.5:c.814G>T, NM_000277.1(PAH):c.814G>T (p.Gly272Ter)",CA251532
102650,12,102894776.0,102894776.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency: 0.00009 in gnomAD; PS3: 26% PAH enzyme activity; PM3_Strong: Detected with Y414C, pathogenic in ClinVar and V245L (P/LP) (PMID:9429153; PMID:24368688). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3_Strong).","9429153, 24368688",https://erepo.genome.network/evrepo/ui/classification/CA229515/MONDO:0009861/006,False,[G/T],"NM_000277.2:c.311C>A, NC_000012.12:g.102894776G>T, CM000674.2:g.102894776G>T, NC_000012.11:g.103288554G>T, CM000674.1:g.103288554G>T, NC_000012.10:g.101812684G>T, NG_008690.1:g.27827C>A, NG_008690.2:g.68635C>A, NM_000277.1:c.311C>A, XM_011538422.1:c.311C>A, NM_001354304.1:c.311C>A, XM_017019370.2:c.311C>A, NM_000277.3:c.311C>A, ENST00000307000.7:c.296C>A, ENST00000546844.1:c.311C>A, ENST00000548928.1:n.233C>A, ENST00000549111.5:n.407C>A, ENST00000550978.6:n.295C>A, ENST00000551337.5:c.311C>A, ENST00000551988.5:n.400C>A, ENST00000553106.5:c.311C>A, NM_000277.2(PAH):c.311C>A (p.Ala104Asp)",CA229515
607,12,102843790.0,102843790.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.1066-11G>A variant in PAH has been reported in > 76 PKU alleles (BH4 deficiency excluded). (PP4_Moderate; PMID: 23500595; PMID: 8990013). This variant has 0% enzyme activity (PS3; http://www.biopku.org/centralStore/biopku/PAH%20activity.pdf). This variant was detected in trans with multiple known pathogenic variants: p.R243Q, p.R243X, p.R261Q, p.R270K, p.I65T. (PM3_Strong; PMID: 23500595; PMID: 8990013). Computational prediction tools and conservation analysis suggest that the c.1066-11G>A variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Strong","23500595, 8990013, 23500595, 8990013, 1769645",https://erepo.genome.network/evrepo/ui/classification/CA251538/MONDO:0009861/006,False,[C/T],"NM_000277.1:c.1066-11G>A, NC_000012.12:g.102843790C>T, CM000674.2:g.102843790C>T, NC_000012.11:g.103237568C>T, CM000674.1:g.103237568C>T, NC_000012.10:g.101761698C>T, NG_008690.1:g.78813G>A, NG_008690.2:g.119621G>A, XM_011538422.1:c.1009-11G>A, NM_000277.2:c.1066-11G>A, NM_001354304.1:c.1066-11G>A, NM_000277.3:c.1066-11G>A, ENST00000307000.7:c.1051-11G>A, ENST00000549247.6:n.825-11G>A, ENST00000551114.2:n.728-11G>A, ENST00000553106.5:c.1066-11G>A, ENST00000635477.1:n.170-11G>A, ENST00000635528.1:n.581-11G>A, NM_000277.1(PAH):c.1066-11G>A",CA251538
617,12,102840472.0,102840472.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.1243G>A (p.Asp415Asn) variant in PAH has been reported in 3 patients with Hyperphenylalaninemia (BH4 deficiency excluded). (PP4_Moderate; PMID: 1358789). This variant has an extremely low allele frequency (0.0001097 in gnomAD) (PM2; http://gnomad.broadinstitute.org). This variant was detected in trans with R408W, F39L, Y414C, IVS10-11G>A (Pathogenic in ClinVar) (PM3_Very-strong; PMID: 1358789; PMID: 12501224; PMID: 18299955). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong","1358789, 1358789, 18299955, 12501224, 11161839",https://erepo.genome.network/evrepo/ui/classification/CA114364/MONDO:0009861/006,False,[C/A/T],"NM_000277.1:c.1243G>A, NC_000012.12:g.102840472C>T, CM000674.2:g.102840472C>T, NC_000012.11:g.103234250C>T, CM000674.1:g.103234250C>T, NC_000012.10:g.101758380C>T, NG_008690.1:g.82131G>A, NG_008690.2:g.122939G>A, XM_011538422.1:c.1186G>A, NM_000277.2:c.1243G>A, NM_001354304.1:c.1243G>A, NM_000277.3:c.1243G>A, ENST00000307000.7:c.1228G>A, ENST00000551114.2:n.905G>A, ENST00000553106.5:c.1243G>A, ENST00000635477.1:n.347G>A, ENST00000635528.1:n.758G>A, NM_000277.1(PAH):c.1243G>A (p.Asp415Asn)",CA114364
610,12,102852876.0,102852876.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PP4: Detected in 2 unrelated patients (PMID:1682234); PM3: Detected with H170D, pathogenic (PMID:11385716). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PP4, PM3).","1682234, 11385716",https://erepo.genome.network/evrepo/ui/classification/CA229757/MONDO:0009861/006,False,[G/A/C],"NM_000277.1:c.781C>T, NC_000012.12:g.102852876G>A, CM000674.2:g.102852876G>A, NC_000012.11:g.103246654G>A, CM000674.1:g.103246654G>A, NC_000012.10:g.101770784G>A, NG_008690.1:g.69727C>T, NG_008690.2:g.110535C>T, XM_011538422.1:c.781C>T, NM_000277.2:c.781C>T, NM_001354304.1:c.781C>T, NM_000277.3:c.781C>T, ENST00000307000.7:c.766C>T, ENST00000549247.6:n.540C>T, ENST00000553106.5:c.781C>T, NM_000277.1(PAH):c.781C>T (p.Arg261Ter)",CA229757
576,12,102840399.0,102840399.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PS3: abolishes PAH activity due to protein instability (PMID:17935162; PMID:3615198); PM3: (PMID:24941924); PP4_Moderate: Reported in Galician PAH deficiency population. BH4 deficiency ruled out. (PMID:23500595); PVS1: Canonical +1 splice site. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM3, PP4_Moderate, PVS1).","23500595, 24941924, 17935162, 3615198",https://erepo.genome.network/evrepo/ui/classification/CA251522/MONDO:0009861/006,False,[C/A/T],"NM_000277.2:c.1315+1G>A, NC_000012.12:g.102840399C>T, CM000674.2:g.102840399C>T, NC_000012.11:g.103234177C>T, CM000674.1:g.103234177C>T, NC_000012.10:g.101758307C>T, NG_008690.1:g.82204G>A, NG_008690.2:g.123012G>A, NM_000277.1:c.1315+1G>A, XM_011538422.1:c.1258+1G>A, NM_001354304.1:c.1315+1G>A, NM_000277.3:c.1315+1G>A, ENST00000307000.7:c.1300+1G>A, ENST00000551114.2:n.977+1G>A, ENST00000553106.5:c.1315+1G>A, ENST00000635477.1:n.419+1G>A, ENST00000635528.1:n.830+1G>A, NM_000277.2(PAH):c.1315+1G>A",CA251522
593,12,102840474.0,102840474.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM5: c.1240T>C likely pathogenic in ClinVar; PP3: All computational evidence supports deleterious effect. REVEL=0.982; PS3: 50% activity, 50% immunoreactivity (PMID:2044609); PM3_VeryStrong: Patient #41 p.R408W / p.Y414C, Phe 744 @dx and two homozygous individuals. Total of 9 patients with this variant (PMID:22526846; PMID:17935162; PMID:9399896; PMID:21871829; PMID:26542770); PP4_Moderate: BH4 defect excluded in all patients (PMID:22526846). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM5, PP3, PS3, PM3_VeryStrong, PP4_Moderate).","22526846, 21871829, 26542770, 9399896, 17935162, 22526846, 2044609",https://erepo.genome.network/evrepo/ui/classification/CA114362/MONDO:0009861/006,False,[T/C],"NM_000277.1:c.1241A>G, NC_000012.12:g.102840474T>C, CM000674.2:g.102840474T>C, NC_000012.11:g.103234252T>C, CM000674.1:g.103234252T>C, NC_000012.10:g.101758382T>C, NG_008690.1:g.82129A>G, NG_008690.2:g.122937A>G, XM_011538422.1:c.1184A>G, NM_000277.2:c.1241A>G, NM_001354304.1:c.1241A>G, NM_000277.3:c.1241A>G, ENST00000307000.7:c.1226A>G, ENST00000551114.2:n.903A>G, ENST00000553106.5:c.1241A>G, ENST00000635477.1:n.345A>G, ENST00000635528.1:n.756A>G, NM_000277.1(PAH):c.1241A>G (p.Tyr414Cys)",CA114362
582,12,102852875.0,102852875.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP3: tools predict damaging; PS3: 15.5-30% activity (PMID:2014036; PMID:25596310); PM3_VeryStrong: L48S, R408W, S349P, R243X (PMID:25596310; PMID:17935162); PP4_Moderate: (PMID:25596310). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PS3, PM3_VeryStrong, PP4_Moderate).","25596310, 25596310, 17935162, 25596310, 2014036",https://erepo.genome.network/evrepo/ui/classification/CA251528/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.1:c.782G>A, NC_000012.12:g.102852875C>T, CM000674.2:g.102852875C>T, NC_000012.11:g.103246653C>T, CM000674.1:g.103246653C>T, NC_000012.10:g.101770783C>T, NG_008690.1:g.69728G>A, NG_008690.2:g.110536G>A, XM_011538422.1:c.782G>A, NM_000277.2:c.782G>A, NM_001354304.1:c.782G>A, NM_000277.3:c.782G>A, ENST00000307000.7:c.767G>A, ENST00000549247.6:n.541G>A, ENST00000553106.5:c.782G>A, NM_000277.1(PAH):c.782G>A (p.Arg261Gln)",CA251528
592,12,102840477.0,102840477.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PS3: In vitro expression of altered protein in COS cells produces severe decrease of PAH activity (<3%); PM2: Extremely low frequency. ExAC MAF=0.00012; PP4_Moderate: Detected in PKU patients, BH4 deficiency excluded; PP3: Predicted deleterious in SIFT, Polyphen-2, MutationTaster. REVEL=0.895; PM3: Detected with V388M (pathogenic) in 2 patients (PMID:9860305; PMID:21307867). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PS3, PM2, PP4_Moderate, PP3, PM3).","21307867, 9860305",https://erepo.genome.network/evrepo/ui/classification/CA229414/MONDO:0009861/006,False,[C/A/G/T],"NM_000277.1:c.1238G>C, NC_000012.12:g.102840477C>G, CM000674.2:g.102840477C>G, NC_000012.11:g.103234255C>G, CM000674.1:g.103234255C>G, NC_000012.10:g.101758385C>G, NG_008690.1:g.82126G>C, NG_008690.2:g.122934G>C, XM_011538422.1:c.1181G>C, NM_000277.2:c.1238G>C, NM_001354304.1:c.1238G>C, NM_000277.3:c.1238G>C, ENST00000307000.7:c.1223G>C, ENST00000551114.2:n.900G>C, ENST00000553106.5:c.1238G>C, ENST00000635477.1:n.342G>C, ENST00000635528.1:n.753G>C, NM_000277.1(PAH):c.1238G>C (p.Arg413Pro)",CA229414
102632,12,102894877.0,102894879.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP4: Phe>120 umol/L with PKU (PMID:25456745); PM3: In trans with: c.842+2T>A (P, ClinGen) (PMID:25456745); PS3: 0% in BioPKU; PM2: Extremely low frequency. ExAC MAF=0.00012; PM4: In frame deletion. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4, PM3, PS3, PM2, PM4).","25456745, 25456745",https://erepo.genome.network/evrepo/ui/classification/CA229490/MONDO:0009861/006,False,[AAG/-],"NM_000277.1:c.207_209delTTC, NM_000277.1:c.206_208delCTT, NM_000277.1:c.208_210delTCT, NM_000277.1:c.208_210del, XM_011538422.1:c.208_210del, NM_000277.2:c.208_210del, NM_001354304.1:c.208_210del, XM_017019370.2:c.208_210del, NM_000277.3:c.208_210del, ENST00000307000.7:c.193_195del, ENST00000546844.1:c.208_210del, ENST00000548677.2:n.295_297del, ENST00000548928.1:n.130_132del, ENST00000549111.5:n.304_306del, ENST00000550978.6:n.192_194del, ENST00000551337.5:c.208_210del, ENST00000551988.5:n.297_299del, ENST00000553106.5:c.208_210del, ENST00000635500.1:n.176_178del, NC_000012.12:g.102894879_102894881del, CM000674.2:g.102894879_102894881del, NC_000012.11:g.103288657_103288659del, CM000674.1:g.103288657_103288659del, NC_000012.10:g.101812787_101812789del, NG_008690.1:g.27724_27726del, NG_008690.2:g.68532_68534del, NM_000277.1(PAH):c.208_210delTCT (p.Ser70del)",CA229490
612,12,102840492.0,102840492.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM3_Strong: In trans with R408W, IVS4-1G>A, R241C (ClinGen, P) (PMID:1312992; PMID:14722928); PP3: ; PS3: Mutant enzyme activity of 46% in BioPKU (PMID:9860305); PP4_Moderate: ~830 uml/L w/o BH4 deficiency & 823 umol/L, BH4 status unknown (PMID:9860305; PMID:1312992). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM3_Strong, PP3, PS3, PP4_Moderate).","1312992, 9860305, 9860305, 14722928, 1312992",https://erepo.genome.network/evrepo/ui/classification/CA229404/MONDO:0009861/006,False,[C/T],"NM_000277.1:c.1223G>A, NC_000012.12:g.102840492C>T, CM000674.2:g.102840492C>T, NC_000012.11:g.103234270C>T, CM000674.1:g.103234270C>T, NC_000012.10:g.101758400C>T, NG_008690.1:g.82111G>A, NG_008690.2:g.122919G>A, XM_011538422.1:c.1166G>A, NM_000277.2:c.1223G>A, NM_001354304.1:c.1223G>A, NM_000277.3:c.1223G>A, ENST00000307000.7:c.1208G>A, ENST00000551114.2:n.885G>A, ENST00000553106.5:c.1223G>A, ENST00000635477.1:n.327G>A, ENST00000635528.1:n.738G>A, NM_000277.1(PAH):c.1223G>A (p.Arg408Gln)",CA229404
376937,12,102894798.0,102894798.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Uncertain Significance,"PAH-specific ACMG/AMP criteria applied: BP4: Tolerated in SIFT, benign in Polyphen-2, Polymorphism in MutationTaster. REVEL=0.511; PP4: Seen in patient with mild HPA (PMID:17627389). In summary this variant meets criteria to be classified as uncertain significance for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (BP4, PP4).",17627389,https://erepo.genome.network/evrepo/ui/classification/CA6748987/MONDO:0009861/006,False,[T/C/G],"NM_000277.2:c.289A>C, NC_000012.12:g.102894798T>G, CM000674.2:g.102894798T>G, NC_000012.11:g.103288576T>G, CM000674.1:g.103288576T>G, NC_000012.10:g.101812706T>G, NG_008690.1:g.27805A>C, NG_008690.2:g.68613A>C, NM_000277.1:c.289A>C, XM_011538422.1:c.289A>C, NM_001354304.1:c.289A>C, XM_017019370.2:c.289A>C, NM_000277.3:c.289A>C, ENST00000307000.7:c.274A>C, ENST00000546844.1:c.289A>C, ENST00000548928.1:n.211A>C, ENST00000549111.5:n.385A>C, ENST00000550978.6:n.273A>C, ENST00000551337.5:c.289A>C, ENST00000551988.5:n.378A>C, ENST00000553106.5:c.289A>C, NM_000277.2(PAH):c.289A>C (p.Ile97Leu)",CA6748987
619,12,102843683.0,102843683.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low in ExAC and 1000 genomes (PMID:9860305); PS3: PAH activity in COS cell expression system 15% (PMID:9860305); PM3: Compound het with severe mutation (PMID:9860305); PP3: ; PP4: Reported in patient with classic PKU (PMID:9860305). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PS3, PM3, PP3, PP4).","9860305, 9860305, 9860305, 9860305",https://erepo.genome.network/evrepo/ui/classification/CA251543/MONDO:0009861/006,False,[C/G/T],"NM_000277.1:c.1162G>A, NC_000012.12:g.102843683C>T, CM000674.2:g.102843683C>T, NC_000012.11:g.103237461C>T, CM000674.1:g.103237461C>T, NC_000012.10:g.101761591C>T, NG_008690.1:g.78920G>A, NG_008690.2:g.119728G>A, XM_011538422.1:c.1105G>A, NM_000277.2:c.1162G>A, NM_001354304.1:c.1162G>A, NM_000277.3:c.1162G>A, ENST00000307000.7:c.1147G>A, ENST00000549247.6:n.921G>A, ENST00000551114.2:n.824G>A, ENST00000553106.5:c.1162G>A, ENST00000635477.1:n.266G>A, ENST00000635528.1:n.677G>A, NM_000277.1(PAH):c.1162G>A (p.Val388Met)",CA251543
102784,12,102855154.0,102855154.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: V2301 seen in 1 patient with PAH deficiency. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_VeryStrong: Detected in trans with IVS 10-11G>A, L48S, R408W, E390G). Upgraded per ClinGen SVI Workgroup. (PMID:15943553; PMID:21147011). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong).","8268925, 21147011, 15943553, 11161839, 17924342",https://erepo.genome.network/evrepo/ui/classification/CA286506/MONDO:0009861/006,False,[C/T],"NM_000277.1:c.688G>A, NC_000012.12:g.102855154C>T, CM000674.2:g.102855154C>T, NC_000012.11:g.103248932C>T, CM000674.1:g.103248932C>T, NC_000012.10:g.101773062C>T, NG_008690.1:g.67449G>A, NG_008690.2:g.108257G>A, XM_011538422.1:c.688G>A, NM_000277.2:c.688G>A, NM_001354304.1:c.688G>A, XM_017019370.2:c.688G>A, NM_000277.3:c.688G>A, ENST00000307000.7:c.673G>A, ENST00000549111.5:n.784G>A, ENST00000553106.5:c.688G>A, NM_000277.1(PAH):c.688G>A (p.Val230Ile)",CA286506
628,12,102843706.0,102843706.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.1139C>T (p.Thr380Met) variant in PAH has been reported in 1 patient with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8268925). This variant has 28% enzyme activity (PS3; PMID: 27620137). This variant was detected in trans with multiple known pathogenic variants: R408W, R261Q, I65T, F299C (PM3_Very-strong; PMID: 7981714). Computational prediction tools and conservation analysis suggest that the c.1139C>T variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PS3, PM3_Very-strong","8268925, 7981714, 27620137",https://erepo.genome.network/evrepo/ui/classification/CA114369/MONDO:0009861/006,False,[G/A],"NM_000277.1:c.1139C>T, NC_000012.12:g.102843706G>A, CM000674.2:g.102843706G>A, NC_000012.11:g.103237484G>A, CM000674.1:g.103237484G>A, NC_000012.10:g.101761614G>A, NG_008690.1:g.78897C>T, NG_008690.2:g.119705C>T, XM_011538422.1:c.1082C>T, NM_000277.2:c.1139C>T, NM_001354304.1:c.1139C>T, NM_000277.3:c.1139C>T, ENST00000307000.7:c.1124C>T, ENST00000549247.6:n.898C>T, ENST00000551114.2:n.801C>T, ENST00000553106.5:c.1139C>T, ENST00000635477.1:n.243C>T, ENST00000635528.1:n.654C>T, NM_000277.1(PAH):c.1139C>T (p.Thr380Met)",CA114369
594,12,102866664.0,102866664.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Not present in ExAC or 1000 genomes (PMID:9860305); PVS1: Canonical -1 splice site where LOF is a known mechanism of disease, exon skipping disrupts reading frame, and is predicted to undergo NMD. Coding exon 5 is present in biologically-relevant transcript. PP4_Moderate: Reported in a mild PKU patient. BH4 deficiency assessed. (PMID:14681498). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PVS1, PP4_Moderate).","14681498, 9860305, 21307867, 14681498, 14681498",https://erepo.genome.network/evrepo/ui/classification/CA229550/MONDO:0009861/006,False,[C/G/T],"NM_000277.1:c.442-1G>A, NC_000012.12:g.102866664C>T, CM000674.2:g.102866664C>T, NC_000012.11:g.103260442C>T, CM000674.1:g.103260442C>T, NC_000012.10:g.101784572C>T, NG_008690.1:g.55939G>A, NG_008690.2:g.96747G>A, XM_011538422.1:c.442-1G>A, NM_000277.2:c.442-1G>A, NM_001354304.1:c.442-1G>A, XM_017019370.2:c.442-1G>A, NM_000277.3:c.442-1G>A, ENST00000307000.7:c.427-1G>A, ENST00000549111.5:n.538-1G>A, ENST00000551988.5:n.530+10798G>A, ENST00000553106.5:c.442-1G>A, NM_000277.1(PAH):c.442-1G>A",CA229550
102803,12,102852936.0,102852936.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC (0.00014) and gnomAD (0.0001301); PP3: Deleterious effect predicted in SIFT, PolyPhen2, MutationTaster; PP4_Moderate: Seen in multiple PKU patients. BH4 deficiency excluded in 2 patients. Upgraded per ClinGen Metabolic Workgroup. (PMID:8222245; PMID:11142755); PM3_Strong: R241C seen once in trans with R413P, and once with R243Q, both pathogenic. Upgraded per ClinGen SVI Workgroup. (PMID:11142755); PS3: In vitro PAH R241C mutant was found to have 25% PAH activity of normal. In vivo phenylalanine breath test measured a decreased level in R241C homozygote. (PMID:15319459; PMID:7915167). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PP4_Moderate, PM3_Strong, PS3).","11142755, 8222245, 15319459, 7915167, 11142755",https://erepo.genome.network/evrepo/ui/classification/CA273357/MONDO:0009861/006,False,[G/A/T],"NM_000277.1:c.721C>T, NC_000012.12:g.102852936G>A, CM000674.2:g.102852936G>A, NC_000012.11:g.103246714G>A, CM000674.1:g.103246714G>A, NC_000012.10:g.101770844G>A, NG_008690.1:g.69667C>T, NG_008690.2:g.110475C>T, XM_011538422.1:c.721C>T, NM_000277.2:c.721C>T, NM_001354304.1:c.721C>T, NM_000277.3:c.721C>T, ENST00000307000.7:c.706C>T, ENST00000549247.6:n.480C>T, ENST00000553106.5:c.721C>T, NM_000277.1(PAH):c.721C>T (p.Arg241Cys)",CA273357
102804,12,102852935.0,102852935.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Extremely low frequency in ExAC, gnomAD, 1000G, ESP (0.000077- 0.0001518); PP3: Predicted deleterious in SIFT, PolyPhen2, MutationTaster; PM5: R241C (VarID 102803) is Pathogenic in ClinVar based on 3 submitters; PP4_Moderate: R241H seen in 1 PKU patient. BH4 deficiency ruled out. Upgraded per ClinGen Metabolism WG. (PMID:8268925); PM3_Strong: R241H detected in trans with pathogenic variants (IVS10, R408W, R252W). Upgraded per ClinGen SVI Workgroup. (PMID:9429153). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM5, PP4_Moderate, PM3_Strong).","8268925, 9429153",https://erepo.genome.network/evrepo/ui/classification/CA286507/MONDO:0009861/006,False,[C/A/T],"NM_000277.1:c.722G>A, NC_000012.12:g.102852935C>T, CM000674.2:g.102852935C>T, NC_000012.11:g.103246713C>T, CM000674.1:g.103246713C>T, NC_000012.10:g.101770843C>T, NG_008690.1:g.69668G>A, NG_008690.2:g.110476G>A, XM_011538422.1:c.722G>A, NM_000277.2:c.722G>A, NM_001354304.1:c.722G>A, NM_000277.3:c.722G>A, ENST00000307000.7:c.707G>A, ENST00000549247.6:n.481G>A, ENST00000553106.5:c.722G>A, NM_000277.1(PAH):c.722G>A (p.Arg241His)",CA286507
92731,12,102840507.0,102840507.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP4_Moderate: Seen on 3 PKU alleles, BH4 deficiency was ruled out. Upgraded per ClinGen Metabolic WG. (PMID:8268925); PM3_VeryStrong: A403V found with 4 pathogenic variants . Upgraded per ClinGen SVI workgroup. (PMID:9429153); PS3: In vitro A403V mutant protein activity was ~43% wt. (PMID:21820508). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong, PS3).","8268925, 9429153, 21820508",https://erepo.genome.network/evrepo/ui/classification/CA273106/MONDO:0009861/006,False,[G/A],"NM_000277.1:c.1208C>T, NC_000012.12:g.102840507G>A, CM000674.2:g.102840507G>A, NC_000012.11:g.103234285G>A, CM000674.1:g.103234285G>A, NC_000012.10:g.101758415G>A, NG_008690.1:g.82096C>T, NG_008690.2:g.122904C>T, XM_011538422.1:c.1151C>T, NM_000277.2:c.1208C>T, NM_001354304.1:c.1208C>T, NM_000277.3:c.1208C>T, ENST00000307000.7:c.1193C>T, ENST00000551114.2:n.870C>T, ENST00000553106.5:c.1208C>T, ENST00000635477.1:n.312C>T, ENST00000635528.1:n.723C>T, NM_000277.1(PAH):c.1208C>T (p.Ala403Val)",CA273106
601,12,102843648.0,102843648.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.1197A>T (p.Val399=) variant in PAH has been reported on 7 alleles of PKU patients (BH4 deficiency excluded). (PP4_Moderate; PMID: 23271928; PMID: 11214902). This variant has an extremely low allele frequency (0.000004064) in gnomAD (PM2; http://gnomAD.broadinstitute.org). This variant induces post-transcriptional skipping of exon 11 (PS3; PMID: 11214902). This variant was detected in trans with R408W (Pathogenic in ClinVar) (PM3; PMID: 11214902). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate","11214902, 23271928, 11214902, 11214902",https://erepo.genome.network/evrepo/ui/classification/CA229379/MONDO:0009861/006,False,[T/A],"NM_000277.1:c.1197A>T, NC_000012.12:g.102843648T>A, CM000674.2:g.102843648T>A, NC_000012.11:g.103237426T>A, CM000674.1:g.103237426T>A, NC_000012.10:g.101761556T>A, NG_008690.1:g.78955A>T, NG_008690.2:g.119763A>T, XM_011538422.1:c.1140A>T, NM_000277.2:c.1197A>T, NM_001354304.1:c.1197A>T, NM_000277.3:c.1197A>T, ENST00000307000.7:c.1182A>T, ENST00000549247.6:n.956A>T, ENST00000551114.2:n.859A>T, ENST00000553106.5:c.1197A>T, ENST00000635477.1:n.301A>T, ENST00000635528.1:n.712A>T, NM_000277.1(PAH):c.1197A>T (p.Val399=)",CA229379
625,12,102843676.0,102843676.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.1169A>G (p.Glu390Gly) variant in PAH has been reported on at least 47 alleles, most often with Mild Hyperphenylalaninemia. (BH4 deficiency excluded). (PP4_Moderate; PMID: 8088845; PMID: 21147011). This variant has an extremely low allele frequency (MAF=0.00018 in gnomAD) (PM2; http://gnomAD.broadinstitute.org). This variant was detected in trans with IVS-12nt1, L333F (Pathogenic in ClinVar) + 8 homozygotes (PM3_Very-strong; PMID: 10479481; PMID: 21147011; PMID: 8088845). Computational prediction tools and conservation analysis suggest that the c.1169A>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong","8088845, 21147011, 10479481, 8088845, 21147011, 10479481, 21147011",https://erepo.genome.network/evrepo/ui/classification/CA114367/MONDO:0009861/006,False,[T/C],"NM_000277.1:c.1169A>G, NC_000012.12:g.102843676T>C, CM000674.2:g.102843676T>C, NC_000012.11:g.103237454T>C, CM000674.1:g.103237454T>C, NC_000012.10:g.101761584T>C, NG_008690.1:g.78927A>G, NG_008690.2:g.119735A>G, XM_011538422.1:c.1112A>G, NM_000277.2:c.1169A>G, NM_001354304.1:c.1169A>G, NM_000277.3:c.1169A>G, ENST00000307000.7:c.1154A>G, ENST00000549247.6:n.928A>G, ENST00000551114.2:n.831A>G, ENST00000553106.5:c.1169A>G, ENST00000635477.1:n.273A>G, ENST00000635528.1:n.684A>G, NM_000277.1(PAH):c.1169A>G (p.Glu390Gly)",CA114367
92751,12,102851701.0,102851701.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PP3: Deleterious in SIFT, Polyphen2, MutationTaster; PP4_Moderate: A300S found on 56/588 hyperphenylalaninemic patients, BH4 deficiency excluded. Upgraded per ClinGen Metabolic WG. (PMID:21147011); PM3_VeryStrong: Detected with c.1066-11G>A (P), R261Q(P/LP), L48S (P), R176X (P) in 20 patients. (PMID:21147011); PS3: A300S in vitro PAH activity of 31% (PMID:17935162). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP3, PP4_Moderate, PM3_VeryStrong, PS3).","21147011, 21147011, 17935162",https://erepo.genome.network/evrepo/ui/classification/CA273108/MONDO:0009861/006,False,[C/A],"NM_000277.1:c.898G>T, NC_000012.12:g.102851701C>A, CM000674.2:g.102851701C>A, NC_000012.11:g.103245479C>A, CM000674.1:g.103245479C>A, NC_000012.10:g.101769609C>A, NG_008690.1:g.70902G>T, NG_008690.2:g.111710G>T, XM_011538422.1:c.898G>T, NM_000277.2:c.898G>T, NM_001354304.1:c.898G>T, NM_000277.3:c.898G>T, ENST00000307000.7:c.883G>T, ENST00000549247.6:n.657G>T, ENST00000551114.2:n.560G>T, ENST00000553106.5:c.898G>T, ENST00000635477.1:n.59G>T, NM_000277.1(PAH):c.898G>T (p.Ala300Ser)",CA273108
588,12,102852930.0,102852930.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: nonsense variant; PS3: <1% of normal PAH activity (PMID:2014036). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PS3).",2014036,https://erepo.genome.network/evrepo/ui/classification/CA220585/MONDO:0009861/006,False,[G/A],"NM_000277.2:c.727C>T, NC_000012.12:g.102852930G>A, CM000674.2:g.102852930G>A, NC_000012.11:g.103246708G>A, CM000674.1:g.103246708G>A, NC_000012.10:g.101770838G>A, NG_008690.1:g.69673C>T, NG_008690.2:g.110481C>T, NM_000277.1:c.727C>T, XM_011538422.1:c.727C>T, NM_001354304.1:c.727C>T, NM_000277.3:c.727C>T, ENST00000307000.7:c.712C>T, ENST00000549247.6:n.486C>T, ENST00000553106.5:c.727C>T, NM_000277.2(PAH):c.727C>T (p.Arg243Ter)",CA220585
584,12,102852903.0,102852903.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: gnomAD MAF: 0.00006; PP3: tools predict damaging ; PS3: 1% residual activity (PMID:25596310; PMID:17935162); PP4: Detection of codon 252arg>trp in a patient with PAH deficiency (PMID:2574153); PM3: Detected with IVS10-11G>A, R261Q, IVS12+1, R68S (all P/LP). (PMID:18299955; PMID:11524738). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PP4, PM3).","2574153, 18299955, 11524738, 25596310, 17935162",https://erepo.genome.network/evrepo/ui/classification/CA251529/MONDO:0009861/006,False,[G/A/C/T],"NM_000277.1:c.754C>T, NC_000012.12:g.102852903G>A, CM000674.2:g.102852903G>A, NC_000012.11:g.103246681G>A, CM000674.1:g.103246681G>A, NC_000012.10:g.101770811G>A, NG_008690.1:g.69700C>T, NG_008690.2:g.110508C>T, XM_011538422.1:c.754C>T, NM_000277.2:c.754C>T, NM_001354304.1:c.754C>T, NM_000277.3:c.754C>T, ENST00000307000.7:c.739C>T, ENST00000549247.6:n.513C>T, ENST00000553106.5:c.754C>T, NM_000277.1(PAH):c.754C>T (p.Arg252Trp)",CA251529
102824,12,102852902.0,102852902.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: ; PP3: tools predict damaging; PS3: BioPKU 3% enzyme activity; 3.8% residual activity (PMID:24401910); PM3: Detected in trans with p.Pro407fs (PMID:7833954); PP4_Moderate: Detected in 2 patients with classic PKU (Phe>1.5mM). BH4 deficiency excluded (PMID:7833954; PMID:9634518). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate).","9634518, 7833954, 7833954, 24401910",https://erepo.genome.network/evrepo/ui/classification/CA229743/MONDO:0009861/006,False,[C/G/T],"NM_000277.1:c.755G>A, NC_000012.12:g.102852902C>T, CM000674.2:g.102852902C>T, NC_000012.11:g.103246680C>T, CM000674.1:g.103246680C>T, NC_000012.10:g.101770810C>T, NG_008690.1:g.69701G>A, NG_008690.2:g.110509G>A, XM_011538422.1:c.755G>A, NM_000277.2:c.755G>A, NM_001354304.1:c.755G>A, NM_000277.3:c.755G>A, ENST00000307000.7:c.740G>A, ENST00000549247.6:n.514G>A, ENST00000553106.5:c.755G>A, NM_000277.1(PAH):c.755G>A (p.Arg252Gln)",CA229743
92747,12,102855204.0,102855204.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.638T>C (p.Leu213Pro) variant in PAH has been reported in in 4 patients with PAH deficiency (BH4 deficiency excluded). (PP4_Moderate; PMID: 8659548; PMID: 19292873; PMID: 21147011). This variant is absent from large population studies (PM2; http://exac.broadinstitute.org). This variant was detected in trans with c.1066-11G>A, E390G, D415N, R261X.(Pathogenic in ClinVar) (PM3_Very-strong; PMID: 19292873; PMID: 21147011; PMID: 8632937). Computational prediction tools and conservation analysis suggest that the c.638T>C variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM3_Very-strong","21147011, 19292873, 8659548, 8632937, 21147011, 19292873",https://erepo.genome.network/evrepo/ui/classification/CA273109/MONDO:0009861/006,False,[A/G],"NM_000277.1:c.638T>C, NC_000012.12:g.102855204A>G, CM000674.2:g.102855204A>G, NC_000012.11:g.103248982A>G, CM000674.1:g.103248982A>G, NC_000012.10:g.101773112A>G, NG_008690.1:g.67399T>C, NG_008690.2:g.108207T>C, XM_011538422.1:c.638T>C, NM_000277.2:c.638T>C, NM_001354304.1:c.638T>C, XM_017019370.2:c.638T>C, NM_000277.3:c.638T>C, ENST00000307000.7:c.623T>C, ENST00000549111.5:n.734T>C, ENST00000553106.5:c.638T>C, NM_000277.1(PAH):c.638T>C (p.Leu213Pro)",CA273109
92753,12,102846938.0,102846938.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Low frequency. 1.0e-5; PP3: All databases agree on damaging effect. REVEL=0.921; PS3: Enzyme activity = 30% (Ho, 2008) (PMID:18590700); PM3: Single patient with classic PKU, c.842C>T (pathogenic in ClinVar) / c.926C>T (PMID:26666653); PP4: Single patient with classic PKU (>1200umol/L), BH4 defect not excluded (PMID:26666653). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4).","26666653, 26666653, 18590700",https://erepo.genome.network/evrepo/ui/classification/CA220592/MONDO:0009861/006,False,[G/A/T],"NM_000277.1:c.926C>T, NC_000012.12:g.102846938G>A, CM000674.2:g.102846938G>A, NC_000012.11:g.103240716G>A, CM000674.1:g.103240716G>A, NC_000012.10:g.101764846G>A, NG_008690.1:g.75665C>T, NG_008690.2:g.116473C>T, XM_011538422.1:c.913-2507C>T, NM_000277.2:c.926C>T, NM_001354304.1:c.926C>T, NM_000277.3:c.926C>T, ENST00000307000.7:c.911C>T, ENST00000549247.6:n.685C>T, ENST00000551114.2:n.588C>T, ENST00000553106.5:c.926C>T, ENST00000635477.1:n.74-2507C>T, ENST00000635528.1:n.441C>T, NM_000277.1(PAH):c.926C>T (p.Ala309Val)",CA220592
618,12,102846948.0,102846948.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: MAF = 2.0e-5; PP3: Software agrees on a damaging effect.; PS3: Mutation ID#1, 18% residual enzyme activity (PMID:18590700); PM3: I306V / F55L (pathogenic in ClinVar) in a single patient with mild HPA (PMID:18299955); PP4_Moderate: BH4 defect excluded in all patients--single patient with mild hyperphe (Bercovich, 2008). (PMID:18299955). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PS3, PM3, PP4_Moderate).","18299955, 18299955, 18590700",https://erepo.genome.network/evrepo/ui/classification/CA114365/MONDO:0009861/006,False,[T/C],"NM_000277.1:c.916A>G, NC_000012.12:g.102846948T>C, CM000674.2:g.102846948T>C, NC_000012.11:g.103240726T>C, CM000674.1:g.103240726T>C, NC_000012.10:g.101764856T>C, NG_008690.1:g.75655A>G, NG_008690.2:g.116463A>G, XM_011538422.1:c.913-2517A>G, NM_000277.2:c.916A>G, NM_001354304.1:c.916A>G, NM_000277.3:c.916A>G, ENST00000307000.7:c.901A>G, ENST00000549247.6:n.675A>G, ENST00000551114.2:n.578A>G, ENST00000553106.5:c.916A>G, ENST00000635477.1:n.74-2517A>G, ENST00000635528.1:n.431A>G, NM_000277.1(PAH):c.916A>G (p.Ile306Val)",CA114365
102720,12,102855322.0,102855322.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: Not found in any population databases; PP3: All predictors agree--damaging; PM3: Single patient IVS4+5G>T (null) / I174V (Bercovich 2008 PMID 18299955) (PMID:18299955); PP4: Two independent patients (one in Zschocke (PMID 10394930) and one in Bercovich (PMID 18299955) with ""PKU"". While no specific levels are mentioned, they are followed in clinic and were diagnosed with Phe >120umol/L. BH4 defect WAS NOT excluded in either paper.. In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP3, PM3, PP4).",18299955,https://erepo.genome.network/evrepo/ui/classification/CA229603/MONDO:0009861/006,False,[T/C],"NM_000277.1:c.520A>G, NC_000012.12:g.102855322T>C, CM000674.2:g.102855322T>C, NC_000012.11:g.103249100T>C, CM000674.1:g.103249100T>C, NC_000012.10:g.101773230T>C, NG_008690.1:g.67281A>G, NG_008690.2:g.108089A>G, XM_011538422.1:c.520A>G, NM_000277.2:c.520A>G, NM_001354304.1:c.520A>G, XM_017019370.2:c.520A>G, NM_000277.3:c.520A>G, ENST00000307000.7:c.505A>G, ENST00000549111.5:n.616A>G, ENST00000551988.5:n.541A>G, ENST00000553106.5:c.520A>G, NM_000277.1(PAH):c.520A>G (p.Ile174Val)",CA229603
92744,12,102866597.0,102866597.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"The c.508C>G (p.His170Asp) variant in PAH has been reported in 1 patient with hyperphenylalaninemia, and 1 patient with benign persistent hyperphenylalaninemia. (PP4; PMID: 11385716). This variant has an extremely low allele frequency (0.00018) in gnomAD (PM2; http://gnomad.broadinstitute.org). This variant has 43% enzyme activity (PS3; PMID: 17935162). This variant was detected in trans with R261X, c.60+5G>T, c.1315+1G>A  (Pathogenic in ClinVar) (PM3_Strong; PMID: 11385716; PMID: 24941924). Computational prediction tools and conservation analysis suggest that the c.829T>G variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PS3, PM3_Strong","11385716, 17935162, 11385716, 24941924",https://erepo.genome.network/evrepo/ui/classification/CA273111/MONDO:0009861/006,False,[G/C],"NM_000277.1:c.508C>G, NC_000012.12:g.102866597G>C, CM000674.2:g.102866597G>C, NC_000012.11:g.103260375G>C, CM000674.1:g.103260375G>C, NC_000012.10:g.101784505G>C, NG_008690.1:g.56006C>G, NG_008690.2:g.96814C>G, XM_011538422.1:c.508C>G, NM_000277.2:c.508C>G, NM_001354304.1:c.508C>G, XM_017019370.2:c.508C>G, NM_000277.3:c.508C>G, ENST00000307000.7:c.493C>G, ENST00000549111.5:n.604C>G, ENST00000551988.5:n.530+10865C>G, ENST00000553106.5:c.508C>G, NM_000277.1(PAH):c.508C>G (p.His170Asp)",CA273111
102698,12,102866615.0,102866615.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Likely Pathogenic,"PAH-specific ACMG/AMP criteria applied: PM2: ExAC MAF: 0.00012; PP4_Moderate: Detected in patients with PKU/HPA. BH4 deficiency excluded. (PMID:11244681; PMID:23942198); PM3_Strong: Detected with D145V, A403V (Pathogenic) (PMID:11244681; PMID:23942198). In summary this variant meets criteria to be classified as likely pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PM2, PP4_Moderate, PM3_Strong).","23942198, 11244681, 23942198, 11244681",https://erepo.genome.network/evrepo/ui/classification/CA229576/MONDO:0009861/006,False,[T/C],"NM_000277.2:c.490A>G, NC_000012.12:g.102866615T>C, CM000674.2:g.102866615T>C, NC_000012.11:g.103260393T>C, CM000674.1:g.103260393T>C, NC_000012.10:g.101784523T>C, NG_008690.1:g.55988A>G, NG_008690.2:g.96796A>G, NM_000277.1:c.490A>G, XM_011538422.1:c.490A>G, NM_001354304.1:c.490A>G, XM_017019370.2:c.490A>G, NM_000277.3:c.490A>G, ENST00000307000.7:c.475A>G, ENST00000549111.5:n.586A>G, ENST00000551988.5:n.530+10847A>G, ENST00000553106.5:c.490A>G, NM_000277.2(PAH):c.490A>G (p.Ile164Val)",CA229576
595,12,102843777.0,102843777.0,ENSG00000171759,PAH,MONDO:0009861,phenylketonuria,Autosomal recessive inheritance,Pathogenic,"PAH-specific ACMG/AMP criteria applied: PVS1: Nonsense variant; PM2: ExAC MAF:0.00006.; PP4_Moderate: seen in classic and mild PKU patients. BH4 deficiency excluded.. In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PVS1, PM2, PP4_Moderate).",,https://erepo.genome.network/evrepo/ui/classification/CA229327/MONDO:0009861/006,False,[G/A/C/T],"NM_000277.2:c.1068C>G, NC_000012.12:g.102843777G>C, CM000674.2:g.102843777G>C, NC_000012.11:g.103237555G>C, CM000674.1:g.103237555G>C, NC_000012.10:g.101761685G>C, NG_008690.1:g.78826C>G, NG_008690.2:g.119634C>G, NM_000277.1:c.1068C>G, XM_011538422.1:c.1011C>G, NM_001354304.1:c.1068C>G, NM_000277.3:c.1068C>G, ENST00000307000.7:c.1053C>G, ENST00000549247.6:n.827C>G, ENST00000551114.2:n.730C>G, ENST00000553106.5:c.1068C>G, ENST00000635477.1:n.172C>G, ENST00000635528.1:n.583C>G, NM_000277.2(PAH):c.1068C>G (p.Tyr356Ter)",CA229327
142269,10,87957955.0,87957955.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Pathogenic,"PTEN c.737C>T (p.P246L) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 23934111, internal laboratory contributor(s) SCV000222227.10)PS4: Probands with phenotype specificity score of 4-15.5. (PMID 24375884, PMID 10076877, PMID 22261759, PMID 23934111, internal laboratory contributor(s) SCV000222227.10)PM2: Absent in large sequenced populations. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",,https://erepo.genome.network/evrepo/ui/classification/CA000559/MONDO:0017623/003,False,[C/T],"NM_000314.6:c.737C>T, NM_000314.5:c.737C>T, NM_001304717.2:c.1256C>T, NM_001304718.1:c.146C>T, XM_006717926.2:c.692C>T, XM_011539981.1:c.737C>T, XM_011539982.1:c.641C>T, XR_945791.1:n.1307C>T, NM_000314.7:c.737C>T, NM_001304717.5:c.1256C>T, NM_001304718.2:c.146C>T, ENST00000371953.7:c.737C>T, ENST00000472832.2:n.164C>T, NC_000010.11:g.87957955C>T, CM000672.2:g.87957955C>T, NC_000010.10:g.89717712C>T, CM000672.1:g.89717712C>T, NC_000010.9:g.89707692C>T, NG_007466.2:g.99517C>T, LRG_311:g.99517C>T, NM_000314.6(PTEN):c.737C>T (p.Pro246Leu)",CA000559
127662,10,87863299.0,87863299.0,ENSG00000227268,KLLN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,"PTEN c.-1170C>T (NC_000010.10: g.89623056C>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000149466.6, SCV000184146.1)",,https://erepo.genome.network/evrepo/ui/classification/CA151481/MONDO:0017623/003,False,[C/A/G/T],"NM_000314.6:c.-1170C>T, NM_001126049.1:c.-812G>A, ENST00000371953.7:c.-1171C>T, ENST00000445946.3:c.-812G>A, NC_000010.11:g.87863299C>T, CM000672.2:g.87863299C>T, NC_000010.10:g.89623056C>T, CM000672.1:g.89623056C>T, NC_000010.9:g.89613036C>T, NG_007466.2:g.4862C>T, LRG_311:g.4862C>T, NG_033079.1:g.5139G>A, NM_000314.6(PTEN):c.-1170C>T",CA151481
185989,10,87925560.0,87925560.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,PTEN c.209+3A>T (IVS3+3A>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Absent in large sequenced populationsPP3: At least 2 out of 3 in silico models predict a splicing impact.,,https://erepo.genome.network/evrepo/ui/classification/CA000135/MONDO:0017623/003,False,[A/G/T],"NM_000314.6:c.209+3A>T, NM_000314.5:c.209+3A>T, NM_001304717.2:c.728+3A>T, NM_001304718.1:c.-541-5486A>T, XM_006717926.2:c.165-5486A>T, XM_011539981.1:c.209+3A>T, XM_011539982.1:c.113+3A>T, XR_945789.1:n.921+3A>T, XR_945790.1:n.921+3A>T, XR_945791.1:n.921+3A>T, NM_000314.7:c.209+3A>T, NM_001304717.5:c.728+3A>T, NM_001304718.2:c.-541-5486A>T, NM_000314.8:c.209+3A>T, ENST00000371953.7:c.209+3A>T, ENST00000498703.1:n.35+3A>T, ENST00000610634.1:c.107+3A>T, NC_000010.11:g.87925560A>T, CM000672.2:g.87925560A>T, NC_000010.10:g.89685317A>T, CM000672.1:g.89685317A>T, NC_000010.9:g.89675297A>T, NG_007466.2:g.67122A>T, LRG_311:g.67122A>T, NM_000314.6(PTEN):c.209+3A>T",CA000135
41682,10,87931071.0,87931071.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Likely Benign,"PTEN c.235G>A (p.A79T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).BS1: Allele frequency of 0.0045 (0.45%, 9/1984 alleles) in the GME variome. (PMID 27428751)BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000222198.12)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",,https://erepo.genome.network/evrepo/ui/classification/CA000358/MONDO:0017623/003,False,[G/A/C/T],"NM_000314.6:c.235G>A, NM_000314.5:c.235G>A, NM_001304717.2:c.754G>A, NM_001304718.1:c.-516G>A, XM_006717926.2:c.190G>A, XM_011539981.1:c.235G>A, XM_011539982.1:c.139G>A, XR_945789.1:n.947G>A, XR_945790.1:n.947G>A, XR_945791.1:n.947G>A, NM_000314.7:c.235G>A, NM_001304717.5:c.754G>A, NM_001304718.2:c.-516G>A, ENST00000371953.7:c.235G>A, ENST00000498703.1:n.61G>A, ENST00000610634.1:c.133G>A, NC_000010.11:g.87931071G>A, CM000672.2:g.87931071G>A, NC_000010.10:g.89690828G>A, CM000672.1:g.89690828G>A, NC_000010.9:g.89680808G>A, NG_007466.2:g.72633G>A, LRG_311:g.72633G>A, NM_000314.6(PTEN):c.235G>A (p.Ala79Thr)",CA000358
142681,10,87933062.0,87933063.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,PTEN c.304_306dupAAA (p.K102_P103insK) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533).,,https://erepo.genome.network/evrepo/ui/classification/CA169101/MONDO:0017623/003,False,[A/-/AAAA],"NM_000314.6:c.304_306dupAAA, NM_000314.5:c.304_306dup, NM_000314.6:c.304_306dup, NM_001304717.2:c.823_825dup, NM_001304718.1:c.-447_-445dup, XM_006717926.2:c.259_261dup, XM_011539981.1:c.304_306dup, XM_011539982.1:c.208_210dup, XR_945789.1:n.1016_1018dup, XR_945790.1:n.1016_1018dup, XR_945791.1:n.1016_1018dup, NM_000314.7:c.304_306dup, NM_001304717.5:c.823_825dup, NM_001304718.2:c.-447_-445dup, ENST00000371953.7:c.304_306dup, ENST00000498703.1:n.130_132dup, ENST00000610634.1:c.202_204dup, NC_000010.11:g.87933063_87933065dup, CM000672.2:g.87933063_87933065dup, NC_000010.10:g.89692820_89692822dup, CM000672.1:g.89692820_89692822dup, NC_000010.9:g.89682800_89682802dup, NG_007466.2:g.74625_74627dup, LRG_311:g.74625_74627dup, NM_000314.6(PTEN):c.304_306dupAAA (p.Lys102_Pro103insLys)",CA169101
127687,10,87965310.0,87965312.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,PTEN c.1052_1054delTAG (p.Val351del) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533). BS3_P: In vitro or in vivo functional study or studies showing no damaging effect on protein function but BS3 not met. (PMID 29706350),29706350,https://erepo.genome.network/evrepo/ui/classification/CA000271/MONDO:0017623/003,False,[TAG/-],"NM_000314.6:c.1052_1054delTAG, NC_000010.11:g.87965312_87965314del, CM000672.2:g.87965312_87965314del, NC_000010.10:g.89725069_89725071del, CM000672.1:g.89725069_89725071del, NC_000010.9:g.89715049_89715051del, NG_007466.2:g.106874_106876del, LRG_311:g.106874_106876del, NM_000314.5:c.1052_1054del, NM_000314.6:c.1052_1054del, NM_001304717.2:c.1571_1573del, NM_001304718.1:c.461_463del, XM_006717926.2:c.1007_1009del, XM_011539982.1:c.956_958del, XR_945791.1:n.1622_1624del, NM_000314.7:c.1052_1054del, NM_001304717.5:c.1571_1573del, NM_001304718.2:c.461_463del, NM_000314.8:c.1052_1054del, ENST00000371953.7:c.1052_1054del, NM_000314.6(PTEN):c.1052_1054delTAG (p.Val351del)",CA000271
187673,10,87965431.0,87965431.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,"PTEN c.1171C>T (p.Pro391Ser)PTEN c.1171C>T (p.Pro391Ser) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3: Missense variants with both lipid phosphatase activity AND results from a second assay appropriate to the protein domain demonstrating no statistically significant difference from wild type. (PMID 30993208, 29785012, 29706350)","29785012, 29706350, 30993208",https://erepo.genome.network/evrepo/ui/classification/CA000118/MONDO:0017623/003,False,[C/A/G/T],"NM_000314.6:c.1171C>T, NC_000010.11:g.87965431C>T, CM000672.2:g.87965431C>T, NC_000010.10:g.89725188C>T, CM000672.1:g.89725188C>T, NC_000010.9:g.89715168C>T, NG_007466.2:g.106993C>T, LRG_311:g.106993C>T, NM_000314.5:c.1171C>T, NM_001304717.2:c.1690C>T, NM_001304718.1:c.580C>T, XM_006717926.2:c.1126C>T, XM_011539982.1:c.1075C>T, XR_945791.1:n.1741C>T, NM_000314.7:c.1171C>T, NM_001304717.5:c.1690C>T, NM_001304718.2:c.580C>T, NM_000314.8:c.1171C>T, ENST00000371953.7:c.1171C>T, NM_000314.6(PTEN):c.1171C>T (p.Pro391Ser)",CA000118
7844,10,87863705.0,87863705.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,"PTEN c.-765G>A (AKA c.-764G>A, NC_000010.10:g.89623462G>A) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).No criteria currently apply to this variant.",,https://erepo.genome.network/evrepo/ui/classification/CA000567/MONDO:0017623/003,False,[G/A],"NM_000314.6:c.-764G>A, NC_000010.11:g.87863705G>A, CM000672.2:g.87863705G>A, NC_000010.10:g.89623462G>A, CM000672.1:g.89623462G>A, NC_000010.9:g.89613442G>A, NG_007466.2:g.5268G>A, LRG_311:g.5268G>A, NG_033079.1:g.4733C>T, ENST00000371953.8:c.-765G>A, ENST00000371953.7:c.-765G>A, ENST00000610634.1:c.-867G>A, NM_000314.5:c.-764G>A, NM_001304717.2:c.-245G>A, NM_001304718.1:c.-1469G>A, NM_000314.7:c.-764G>A, NM_001304717.5:c.-245G>A, NM_001304718.2:c.-1469G>A, NM_000314.8:c.-765G>A, NM_000314.8(PTEN):c.-765G>A, NM_000314.6(PTEN):c.-764G>A",CA000567
404147,10,87864513.0,87864513.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Likely Pathogenic,"PTEN c.44G>A (p.Arg15Lys) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (internal laboratory contributor SCV000573362.4)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 25875300)PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (internal laboratory contributor SCV000573362.4)","29785012, 29706350",https://erepo.genome.network/evrepo/ui/classification/CA16613142/MONDO:0017623/003,False,[G/A/C/T],"NM_000314.6:c.44G>A, NC_000010.11:g.87864513G>A, CM000672.2:g.87864513G>A, NC_000010.10:g.89624270G>A, CM000672.1:g.89624270G>A, NC_000010.9:g.89614250G>A, NG_007466.2:g.6075G>A, LRG_311:g.6075G>A, NG_033079.1:g.3925C>T, NM_000314.5:c.44G>A, NM_001304717.2:c.563G>A, NM_001304718.1:c.-662G>A, XM_006717926.2:c.44G>A, XM_011539981.1:c.44G>A, XR_945789.1:n.756G>A, XR_945790.1:n.756G>A, XR_945791.1:n.756G>A, NM_000314.7:c.44G>A, NM_001304717.5:c.563G>A, NM_001304718.2:c.-662G>A, NM_000314.8:c.44G>A, ENST00000371953.7:c.44G>A, ENST00000462694.1:n.46G>A, ENST00000487939.1:n.65G>A, ENST00000610634.1:c.-59G>A, ENST00000618586.1:n.13G>A, NM_000314.6(PTEN):c.44G>A (p.Arg15Lys)",CA16613142
184104,10,87864547.0,87864547.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Uncertain Significance,"PTEN c.78C>T (p.T26=) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",,https://erepo.genome.network/evrepo/ui/classification/CA000203/MONDO:0017623/003,False,[C/A/G/T],"NM_000314.6:c.78C>T, NC_000010.11:g.87864547C>T, CM000672.2:g.87864547C>T, NC_000010.10:g.89624304C>T, CM000672.1:g.89624304C>T, NC_000010.9:g.89614284C>T, NG_007466.2:g.6109C>T, LRG_311:g.6109C>T, NG_033079.1:g.3891G>A, NM_000314.5:c.78C>T, NM_001304717.2:c.597C>T, NM_001304718.1:c.-628C>T, XM_006717926.2:c.78C>T, XM_011539981.1:c.78C>T, XR_945789.1:n.790C>T, XR_945790.1:n.790C>T, XR_945791.1:n.790C>T, NM_000314.7:c.78C>T, NM_001304717.5:c.597C>T, NM_001304718.2:c.-628C>T, NM_000314.8:c.78C>T, ENST00000371953.7:c.78C>T, ENST00000462694.1:n.80C>T, ENST00000487939.1:n.99C>T, ENST00000610634.1:c.-25C>T, ENST00000618586.1:n.47C>T, NM_000314.6(PTEN):c.78C>T (p.Thr26=)",CA000203
187590,10,87925512.0,87925512.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Likely Pathogenic,PTEN c.165-1G>A (IVS2-1G>A) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations,,https://erepo.genome.network/evrepo/ui/classification/CA000129/MONDO:0017623/003,False,[G/A/C/T],"NM_000314.6:c.165-1G>A, NC_000010.11:g.87925512G>A, CM000672.2:g.87925512G>A, NC_000010.10:g.89685269G>A, CM000672.1:g.89685269G>A, NC_000010.9:g.89675249G>A, NG_007466.2:g.67074G>A, LRG_311:g.67074G>A, NM_000314.5:c.165-1G>A, NM_001304717.2:c.684-1G>A, NM_001304718.1:c.-541-5534G>A, XM_006717926.2:c.165-5534G>A, XM_011539981.1:c.165-1G>A, XM_011539982.1:c.69-1G>A, XR_945789.1:n.877-1G>A, XR_945790.1:n.877-1G>A, XR_945791.1:n.877-1G>A, NM_000314.7:c.165-1G>A, NM_001304717.5:c.684-1G>A, NM_001304718.2:c.-541-5534G>A, NM_000314.8:c.165-1G>A, ENST00000371953.7:c.165-1G>A, ENST00000610634.1:c.63-1G>A, NM_000314.6(PTEN):c.165-1G>A",CA000129
189462,10,87894024.0,87894024.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Likely Pathogenic,PTEN 80-1G>C (IVS1-1G>C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations,,https://erepo.genome.network/evrepo/ui/classification/CA000586/MONDO:0017623/003,False,[G/A/C],"NM_000314.6:c.80-1G>C, NC_000010.11:g.87894024G>C, CM000672.2:g.87894024G>C, NC_000010.10:g.89653781G>C, CM000672.1:g.89653781G>C, NC_000010.9:g.89643761G>C, NG_007466.2:g.35586G>C, LRG_311:g.35586G>C, NM_000314.5:c.80-1G>C, NM_001304717.2:c.599-1G>C, NM_001304718.1:c.-626-1G>C, XM_006717926.2:c.80-1G>C, XM_011539981.1:c.80-1G>C, XM_011539982.1:c.68+13586G>C, XR_945789.1:n.792-1G>C, XR_945790.1:n.792-1G>C, XR_945791.1:n.792-1G>C, NM_000314.7:c.80-1G>C, NM_001304717.5:c.599-1G>C, NM_001304718.2:c.-626-1G>C, NM_000314.8:c.80-1G>C, ENST00000371953.7:c.80-1G>C, ENST00000462694.1:n.82-1G>C, ENST00000610634.1:c.-23-1G>C, NM_000314.6(PTEN):c.80-1G>C",CA000586
189441,10,87961076.0,87961079.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Pathogenic,PTEN c.987_990delTAAA (p.N329KfsX14) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10232405),,https://erepo.genome.network/evrepo/ui/classification/CA000656/MONDO:0017623/003,False,[TAAA/-],"NM_000314.6:c.987_990delTAAA, NM_000314.5:c.987_990del, NM_000314.6:c.987_990del, NM_001304717.2:c.1506_1509del, NM_001304718.1:c.396_399del, XM_006717926.2:c.942_945del, XM_011539981.1:c.987_990del, XM_011539982.1:c.891_894del, XR_945791.1:n.1557_1560del, NM_000314.7:c.987_990del, NM_001304717.5:c.1506_1509del, NM_001304718.2:c.396_399del, ENST00000371953.7:c.987_990del, ENST00000472832.2:n.414_417del, NC_000010.11:g.87961079_87961082del, CM000672.2:g.87961079_87961082del, NC_000010.10:g.89720836_89720839del, CM000672.1:g.89720836_89720839del, NC_000010.9:g.89710816_89710819del, NG_007466.2:g.102641_102644del, LRG_311:g.102641_102644del, NM_000314.6(PTEN):c.987_990delTAAA (p.Asn329Lysfs)",CA000656
187657,10,87960984.0,87960984.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Pathogenic,PTEN c.892C>T (p.Q298X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23470840),,https://erepo.genome.network/evrepo/ui/classification/CA000219/MONDO:0017623/003,False,[C/A/G/T],"NM_000314.6:c.892C>T, NC_000010.11:g.87960984C>T, CM000672.2:g.87960984C>T, NC_000010.10:g.89720741C>T, CM000672.1:g.89720741C>T, NC_000010.9:g.89710721C>T, NG_007466.2:g.102546C>T, LRG_311:g.102546C>T, NM_000314.5:c.892C>T, NM_001304717.2:c.1411C>T, NM_001304718.1:c.301C>T, XM_006717926.2:c.847C>T, XM_011539981.1:c.892C>T, XM_011539982.1:c.796C>T, XR_945791.1:n.1462C>T, NM_000314.7:c.892C>T, NM_001304717.5:c.1411C>T, NM_001304718.2:c.301C>T, ENST00000371953.7:c.892C>T, ENST00000472832.2:n.319C>T, NM_000314.6(PTEN):c.892C>T (p.Gln298Ter)",CA000219
185213,10,87961056.0,87961056.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Likely Pathogenic,PTEN c.964A>T (p.Lys322Ter) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations,,https://erepo.genome.network/evrepo/ui/classification/CA000235/MONDO:0017623/003,False,[A/T],"NM_000314.6:c.964A>T, NC_000010.11:g.87961056A>T, CM000672.2:g.87961056A>T, NC_000010.10:g.89720813A>T, CM000672.1:g.89720813A>T, NC_000010.9:g.89710793A>T, NG_007466.2:g.102618A>T, LRG_311:g.102618A>T, NM_000314.5:c.964A>T, NM_001304717.2:c.1483A>T, NM_001304718.1:c.373A>T, XM_006717926.2:c.919A>T, XM_011539981.1:c.964A>T, XM_011539982.1:c.868A>T, XR_945791.1:n.1534A>T, NM_000314.7:c.964A>T, NM_001304717.5:c.1483A>T, NM_001304718.2:c.373A>T, NM_000314.8:c.964A>T, ENST00000371953.7:c.964A>T, ENST00000472832.2:n.391A>T, NM_000314.6(PTEN):c.964A>T (p.Lys322Ter)",CA000235
189411,10,87952136.0,87952136.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Pathogenic,"PTEN c.511C>T (p.Q171X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Absent in large sequenced populations (PMID 27535533).PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 22595938)PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 17043057, PMID 22595938)",,https://erepo.genome.network/evrepo/ui/classification/CA000494/MONDO:0017623/003,False,[C/A/G/T],"NM_000314.6:c.511C>T, NM_000314.5:c.511C>T, NM_001304717.2:c.1030C>T, NM_001304718.1:c.-81C>T, XM_006717926.2:c.466C>T, XM_011539981.1:c.511C>T, XM_011539982.1:c.415C>T, XR_945789.1:n.1382C>T, XR_945790.1:n.1499C>T, XR_945791.1:n.1205-5717C>T, NM_000314.7:c.511C>T, NM_001304717.5:c.1030C>T, NM_001304718.2:c.-81C>T, ENST00000371953.7:c.511C>T, NC_000010.11:g.87952136C>T, CM000672.2:g.87952136C>T, NC_000010.10:g.89711893C>T, CM000672.1:g.89711893C>T, NC_000010.9:g.89701873C>T, NG_007466.2:g.93698C>T, LRG_311:g.93698C>T, NM_000314.6(PTEN):c.511C>T (p.Gln171Ter)",CA000494
141654,10,87864519.0,87864520.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Pathogenic,"PTEN c.50_51delAA (p.Q17RfsX26) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5’ to c.1121 (NM_000314.4).PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 20223021)",20223021,https://erepo.genome.network/evrepo/ui/classification/CA000167/MONDO:0017623/003,False,[AA/-],"NM_000314.6:c.50_51delAA, NM_000314.5:c.50_51del, NM_000314.6:c.50_51del, NM_001304717.2:c.569_570del, NM_001304718.1:c.-656_-655del, XM_006717926.2:c.50_51del, XM_011539981.1:c.50_51del, XR_945789.1:n.762_763del, XR_945790.1:n.762_763del, XR_945791.1:n.762_763del, NM_000314.7:c.50_51del, NM_001304717.5:c.569_570del, NM_001304718.2:c.-656_-655del, ENST00000371953.7:c.50_51del, ENST00000462694.1:n.52_53del, ENST00000487939.1:n.71_72del, ENST00000610634.1:c.-53_-52del, ENST00000618586.1:n.19_20del, NC_000010.11:g.87864519_87864520del, CM000672.2:g.87864519_87864520del, NC_000010.10:g.89624276_89624277del, CM000672.1:g.89624276_89624277del, NC_000010.9:g.89614256_89614257del, NG_007466.2:g.6081_6082del, LRG_311:g.6081_6082del, NG_033079.1:g.3918_3919del, NM_000314.6(PTEN):c.50_51delAA (p.Gln17Argfs)",CA000167
92810,10,87961150.0,87961150.0,ENSG00000171862,PTEN,MONDO:0017623,PTEN hamartoma tumor syndrome,Autosomal dominant inheritance,Benign,"PTEN c.1026+32T>G (IVS8+32T>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation).  Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).BA1: Allele frequency of 0.374 (37.4%, 102,771/274,696 alleles) in the gnomAD cohort. (PMID 27535533)",,https://erepo.genome.network/evrepo/ui/classification/CA000255/MONDO:0017623/003,False,[T/G],"NM_000314.6:c.1026+32T>G, NC_000010.11:g.87961150T>G, CM000672.2:g.87961150T>G, NC_000010.10:g.89720907T>G, CM000672.1:g.89720907T>G, NC_000010.9:g.89710887T>G, NG_007466.2:g.102712T>G, LRG_311:g.102712T>G, NM_000314.5:c.1026+32T>G, NM_001304717.2:c.1545+32T>G, NM_001304718.1:c.435+32T>G, XM_006717926.2:c.981+32T>G, XM_011539981.1:c.1026+32T>G, XM_011539982.1:c.930+32T>G, XR_945791.1:n.1596+32T>G, NM_000314.7:c.1026+32T>G, NM_001304717.5:c.1545+32T>G, NM_001304718.2:c.435+32T>G, ENST00000371953.7:c.1026+32T>G, ENST00000472832.2:n.485T>G, NM_000314.6(PTEN):c.1026+32T>G",CA000255
